Transcatheter mitral valve prosthesis

Description

BACKGROUND OF THE INVENTION
1. Field of the Invention

The present invention generally relates to medical devices and methods, and more particularly relates to the treatment of valve insufficiency, such as mitral insufficiency, also referred to as mitral regurgitation. The use of prosthetic valves delivered by traditional surgical implantation methods, or by less invasive percutaneous catheter or minimally invasive transapical methods are one possible treatment for valvar insufficiency.

The heart of vertebrate animals is divided into four chambers, and is equipped with four valves (the mitral, aortic, pulmonary and tricuspid valves) that ensure that blood pumped by the heart flows in a forward direction through the cardiovascular system. The mitral valve of a healthy heart prevents the backflow of blood from the left ventricle into the left atrium of the heart, and comprises two flexible leaflets (anterior and posterior) that close when the left ventricle contracts. The leaflets are attached to a fibrous annulus, and their free edges are tethered by sub-valvular chordae tendineae to papillary muscles in the left ventricle to prevent them from prolapsing into the left atrium during the contraction of the left ventricle.

Various cardiac diseases or degenerative changes may cause dysfunction in any of these portions of the mitral valve apparatus, causing the mitral valve to become abnormally narrowed or dilated, or to allow blood to leak (i.e. regurgitate) from the left ventricle back into the left atrium. Any such impairments compromise cardiac sufficiency, and can be debilitating or life threatening.

Numerous surgical methods and devices have accordingly been developed to treat mitral valve dysfunction, including open-heart surgical techniques for replacing, repairing or re-shaping the native mitral valve apparatus, and the surgical implantation of various prosthetic devices such as annuloplasty rings to modify the anatomy of the native mitral valve. More recently, less invasive transcatheter techniques for the delivery of replacement mitral valve assemblies have been developed. In such techniques, a prosthetic valve is generally mounted in a crimped state on the end of a flexible catheter and advanced through a blood vessel or the body of the patient until the valve reaches the implantation site. The prosthetic valve is then expanded to its functional size at the site of the defective native valve.

While these devices and methods are promising treatments for valvar insufficiency, they can be difficult to deliver, expensive to manufacture, or may not be indicated for all patients. Therefore, it would be desirable to provide improved devices and methods for the treatment of valvar insufficiency such as mitral insufficiency. At least some of these objectives will be met by the devices and methods disclosed below.

2. Description of the Background Art

By way of example, PCT international patent number PCT/US2008/054410 (published as PCT international publication no. WO2008/103722), the disclosure of which is hereby incorporated by reference, describes a transcatheter mitral valve prosthesis that comprises a resilient ring, a plurality of leaflet membranes mounted with respect to the ring so as to permit blood flow therethrough in one direction, and a plurality of tissue-engaging positioning elements movably mounted with respect to the ring and dimensioned to grip the anatomical structure of the heart valve annulus, heart valve leaflets, and/or heart wall. Each of the positioning elements defines respective proximal, intermediate, and distal tissue engaging regions cooperatively configured and dimensioned to simultaneously engage separate corresponding areas of the tissue of an anatomical structure, and may include respective first, second, and third elongate tissue-piercing elements. The valve prosthesis may also include a skirt mounted with respect to the resilient ring for sealing a periphery of the valve prosthesis against a reverse flow of blood around the valve prosthesis.

PCT international patent number PCT/US2009/041754 (published as PCT international publication no. WO2009/134701), the disclosure of which is hereby incorporated by reference, describes a prosthetic mitral valve assembly that comprises an anchor or outer support frame with a flared upper end and a tapered portion to fit the contours of the native mitral valve, and a tissue-based one-way valve mounted therein. The assembly is adapted to expand radially outwardly and into contact with the native heart tissue to create a pressure fit, and further includes tension members anchoring the leaflets of the valve assembly to a suitable location on the heart to function as prosthetic chordae tendineae.

Also known in the prior art are prosthetic mitral valve assemblies that utilize a claw structure for attachment of the prosthesis to the heart (see, for example, U.S. patent application publication no. US2007/0016286 to Hermann et al., the disclosure of which is hereby incorporated by reference), as are prosthetic mitral valve assemblies that rely on the application of axial rather than radial clamping forces to facilitate the self-positioning and self-anchoring of the prosthesis with respect to the native anatomical structure.

Another method which has been proposed as a treatment of mitral valve regurgitation is the surgical bow tie method, which recently has been adapted into a minimally invasive catheter based treatment where an implant is used to clip the valve leaflets together. This procedure is more fully disclosed in the scientific and patent literature, such as in U.S. Pat. No. 6,629,534 to St. Goar et al., the entire contents of which are incorporated herein by reference.

Other relevant publications include U.S. Patent Publication No. 2011/0015731 to Carpentier et al.

BRIEF SUMMARY OF THE INVENTION

The present invention generally relates to medical devices and methods, and more particularly prosthetic valves used to treat mitral regurgitation. While the present disclosure focuses on the use of a prosthetic valve for treating mitral regurgitation, this is not intended to be limiting. The prosthetic valves disclosed herein may also be used to treat other body valves including other heart valves or venous valves. Exemplary heart valves include the aortic valve, the triscupsid valve, or the pulmonary valve.

In embodiments of the present subject matter, transcatheter mitral valve prostheses and transcatheter methods and systems of deploying the same are provided. In certain embodiments, the mitral valve prosthesis comprises a tissue-type prosthetic one-way valve structure comprising a plurality of leaflets affixed within a self-expanding or expandable anchor (i.e. frame) portion having a geometry that expands into a low profile atrial skirt region, an annular region dimensioned to generally conform to a native mitral valve annulus, a ventricular skirt region that displaces the native mitral valve leaflets, and a plurality of leaflet commissures extending into the sub-annular ventricular space (i.e. in the direction of the outflow of blood through the prosthesis) and configured to optimize the efficiency of the prosthetic valve structure and the load distribution on the leaflets thereof. The anchor portion may also in preferred embodiments be asymmetrical along its longitudinal axis, with the atrial skirt region, the annular region and/or the ventricular skirt region having differently configured anterior and posterior aspects in order to facilitate close accommodation of the asymmetrical contours and features of a typical native mitral valve apparatus. This asymmetry may result inherently from the structural configuration of the anchor portion as discussed further below, and/or as a consequence of shaping or forming steps employed during the manufacturing process.

The prosthetic valve structure in preferred embodiments may comprise a bicuspid or tricuspid valve in order, in part, to simplify manufacture of the mitral valve prosthesis, but as would be readily apparent to those of skill in the art, other configurations are possible. The leaflets may be fabricated from a single piece or from multiple pieces of standard biologic prosthetic materials, such as cryo- or chemically-preserved pericardium (e.g. bovine, equine, porcine, caprine, kangaroo), or from standard suitable synthetic prosthetic materials (e.g. fiber-reinforced matrix materials) well known in the art, and may be sewn or otherwise adhered to the anchor to form the valve leaflets in any standard suitable manner.

To optimize prosthetic valve efficiency and the load distribution on the prosthetic leaflets, the commissures extend generally axially in a cantilevered fashion downstream into the sub-annular space, and are capable of flexing radially and laterally along their axial lengths to distribute the forces associated with blood flow through the prosthetic valve structure. In some embodiments, the commissures define (when the mitral valve prosthesis is in an expended state) a somewhat frustoconical aperture that narrows along the forward direction of blood flow in order to aid in the closure of the prosthetic valve structure during contraction of the ventricle. To further optimize efficiency and load distribution on the leaflets, the commissures may be shaped and dimensioned so as to provide for the attachment of the leaflets along arcuate seams, and may also be made selectively flexible at different points or zones along their axial length through, for example, the addition or deletion of reinforcing struts, or through variation of the thickness of the commissures in selected regions.

The anchor portion of the mitral valve prosthesis is preferably fabricated from a single piece of metallic material that has been cut so as to permit the mitral valve prosthesis to be compressed into a compact, generally tubular delivery configuration, and expanded into the deployment configuration further described herein. In self-expanding embodiments, the anchor portion of the mitral valve prosthesis may be fabricated from a shape memory alloy (SM) such as the nickel-titanium alloy nitinol, and in expandable embodiments, the anchor portion may be fabricated from any metallic material, such as chromium alloy or stainless steel, that is suitable for implantation into the body. In some embodiments, the metallic material may be of a single thickness throughout entirety of the anchor portion, and in others may vary in thickness so as to facilitate variations in the radial force that is exerted by the anchor portion in specific regions thereof, to increase or decrease the flexibility of the anchor portion in certain regions, and/or to control the process of compression in preparation for deployment and the process of expansion during deployment.

When deployed, the atrial skirt region of the mitral valve prosthesis extends generally radially outwards so as to lie flat against and cover the atrial surface of the native mitral valve annulus, and to anchor the mitral valve prosthesis against at least a portion of the adjoining atrial surface of the heart. The atrial skirt region has a low axial profile (extending only slightly into the atrium of the heart) in order to minimize potentially thrombogenic turbulence in blood flow, and in preferred embodiments, may be covered with standard biologic or synthetic prosthetic materials of the sort described above in order to seal the atrial skirt region against the atrial surface and to facilitate the funneling of atrial blood through the mitral valve prosthesis. In some embodiments, the atrial skirt region further comprises atrial barbs or prongs to further facilitate the anchoring of the deployed prosthesis to the atrial heart surface. To facilitate the orientation and alignment of the mitral valve prosthesis within the native mitral valve upon deployment, particularly in embodiments where the anchor portion is longitudinally asymmetrical, the atrial skirt region of the anchor portion of the mitral valve prosthesis may preferably further comprise an alignment structure that may be differentiated (such as by angiography, computed tomography, etc.) from the remainder of the atrial skirt region and thereby used as an orientation guide during deployment. Most preferably, the alignment structure may comprise an elongation of the anterior aspect of the atrial skirt region configured to expand radially to accommodate the aortic root portion of the atrial surface.

The annular region of the mitral valve prosthesis is dimensioned, as noted above, to generally conform to and anchor against a native mitral valve annulus when deployed. In preferred embodiments, the deployed annular region may define a generally D-shaped annulus suitable for fitting the contours of a typical native mitral valve, and may be covered with standard biologic or synthetic prosthetic materials of the sort previously described to seal the annular region against the native mitral valve annulus.

The ventricular skirt region expands when deployed in the ventricular space generally radially outwards against the native mitral valve, but not so far as to obstruct the left ventricular outflow tract, nor to contact the ventricular wall. To anchor the mitral valve prosthesis against the displaced native leaflets in the ventricular space, the maximal radial displacement of the fully deployed ventricular skirt region is selected to be slightly greater than the circumference of the native mitral valve. In preferred embodiments, the ventricular skirt region also comprises ventricular and/or native leaflet barbs or prongs to further anchor the deployed prosthesis thereto. Most preferably, the ventricular skirt region is asymmetrical and the prongs thereof comprise two trigonal anchoring tabs located in the anterior aspect of the ventricular skirt region for anchoring against the fibrous trigones on either side of the anterior leaflet of the native mitral valve, and one posterior ventricular anchoring tab located in the posterior aspect of the ventricular skirt region for anchoring over the posterior leaflet of the native mitral valve. Associated with these tabs are deployment control regions as described in further detail below.

The ventricular skirt region may also in some embodiments be covered with standard biologic or synthetic prosthetic materials of the sort previously described in order to seal the ventricular skirt region against the displaced native leaflets, and thereby to funnel ventricular blood (during contraction of the ventricle) towards the prosthetic valve structure to assist in the closure thereof during contraction of the ventricle.

The combined 3-zone anchoring of the mitral valve prosthesis against the atrial surface, the native valve annulus, and the displaced native leaflets (supplemented, in preferred embodiments by a fourth zone of anchoring from the trigonal and posterior ventricular anchoring) in the ventricular space prevents the prosthesis from migrating or dislodging from within the native valve annulus during the contraction of the atrium or the ventricle, and lessens the anchoring pressure that is required to be applied in any given anchoring zone as compared to a prosthesis that is anchored in only a single anchoring zone, or in any combination of these four anchoring zones. The consequent reduction in radial force required to be exerted against the native structures in each zone minimizes the risk of obstruction or impingement of the nearby aortic valve or aortic root caused by the displacement of the native mitral valve apparatus. The combined 3 or 4-zone anchoring of the mitral valve prosthesis also facilitates the positioning and/or re-positioning of the mitral valve prosthesis as described below.

To deploy the mitral valve prosthesis within the native mitral valve apparatus, the prosthesis is first compacted and loaded into a suitably-adapted conventional catheter delivery system of the sort well known to those of skill in the art. Preferably, to facilitate later deployment, the commissures and associated prosthetic valve structure of the prosthesis are captured within an inner lumen of the catheter delivery system, and the remaining portions of the anchor region are captured within a secondary outer lumen of the catheter delivery system. The loaded mitral valve prosthesis may then be delivered (typically either transseptally or transapically) in its compacted form into the left atrium of the heart using a conventional catheter delivery system. The prosthesis is releasably attached to the catheter delivery system via its commissures, and shielded by the (preferably dual-lumen) delivery sheath thereof during transit into the atrial space. Once the prosthesis has been guided into the left atrium, the delivery sheath of the catheter delivery system is retracted as described below in order to permit expansion of the various regions of the prosthesis to proceed. Of course, in self-expanding embodiments, expansion of the prosthesis will occur spontaneously upon retraction of the delivery sheath, and in expandable embodiments, a catheter inflation structure such as a balloon is required to effect the expansion.

Deployment of the mitral valve prosthesis may proceed differently depending upon the features of the particular embodiment of the prosthesis being deployed. For example, in asymmetrical embodiments that comprise trigonal anchoring tabs and a posterior ventricular anchoring tab in the ventricular skirt region (as well as, (preferably, an alignment structure in the atrial region), these tabs may preferably be deployed before deployment of the remaining portions of the ventricular skirt regions in order to facilitate the anchoring of these tabs against the native fibrous trigones and posterior leaflet, respectively.

In the first general deployment step, the atrial skirt region of the mitral valve prosthesis is permitted to expand by retracting the corresponding portion of the catheter delivery sheath (or is balloon-expanded following the retraction of the corresponding portion of the delivery sheath) within the left atrium of the heart, and the expanded atrial skirt region is then positioned over the atrial surface of the native mitral valve and anchored against at least a portion of the adjoining atrial surface of the heart. In preferred embodiments where the atrial skirt region comprises an alignment structure, this first general deployment step may be further broken down into two sub-steps, wherein the catheter delivery sheath is first retracted only so far as to permit expansion of the alignment structure (so that it may be visualized to facilitate manipulation of the delivery system in such a way as to orient the mitral valve prosthesis into a desired position), and then, once initial alignment of the prosthesis appears to be satisfactory, further retracted to permit the expansion, positioning and anchoring of the remaining portions of the atrial skirt region. In embodiments where the alignment structure comprises an elongation of the anterior aspect of the atrial skirt region, such initial alignment comprises the rotation and/or alignment of the alignment structure so that it is situated adjacent the aortic root and between the fibrous trigones of the native anterior leaflet.

Next, the annular region of the prosthesis is permitted to expand by further retraction of the catheter delivery sheath so as to engage the native mitral valve annulus (i.e. to contact the native valve annulus throughout at least a majority thereof) in order to create a second anchoring zone and to create a suitable opening for blood flow through the prosthetic valve structure.

Then, in embodiments that comprise trigonal anchoring tabs and a posterior ventricular anchoring tab in the ventricular skirt region, the catheter delivery sheath is further retracted so far as to permit the tabs to expand while the remainder of the ventricular skirt region of the prosthesis, including the deployment control regions of the tabs, remain sheathed. With the deployment control regions still retained within the delivery system and the atrial skirt region anchored against the atrial surface, the tabs project radially outward to facilitate engagement with the corresponding features of the native mitral valve. The posterior ventricular anchoring tab is aligned in the middle of the posterior leaflet of the mitral valve where there is an absence of chordae attachments to the posterior leaflet, and passed over the posterior leaflet to seat between the posterior leaflet and the ventricular watt. The two trigonal anchoring tabs are positioned on either side of the anterior leaflet with their heads positioned at the fibrous trigones. Slight rotation and realignment of the prosthesis can occur at this time.

Once the assembly has been satisfactorily positioned and the tabs aligned, the catheter delivery sheath may be further retracted to permit expansion of the remaining portions of the ventricular skirt region to secure the prosthesis within the mitral apparatus and seal the mitral annulus. Complete retraction of the outer catheter delivery sheath releases the ventricular skirt region and allows the anchoring tabs to proximate their anchoring location. As the prosthesis expands, the trigonal tabs anchor against the fibrous trigones, capturing the native anterior leaflet and chordae between the tabs and the anterior surface of the prosthetic valve assembly, and the posterior ventricular tab anchors between the ventricular wall and the posterior leaflet, capturing the posterior leaflet between the posterior anchoring tab and the posterior surface of the prosthetic valve assembly. The remaining portions of the ventricular skirt region expand out against the native mitral valve leaflets and adjacent anatomy, thereby creating a sealing funnel within the native leaflets and displacing the native leaflets from the prosthetic commissures to avoid obstruction of the prosthetic valve function. With the commissures of the prosthesis still captured within the delivery system, very minor adjustments may still made to ensure accurate positioning, anchoring and sealing.

In embodiments that do not comprise trigonal anchoring tabs and a posterior ventricular anchoring tab in the ventricular skirt region, the retraction of the catheter delivery sheath from the ventricular skirt region may, of course, be performed in one step after the atrial skirt and annular regions of the prosthesis have been initially anchored, to permit the ventricular skirt region of the prosthesis to expand against the native mitral valve, and to additionally anchor the prosthesis against the displaced native leaflets in the ventricular space. Optionally, the mitral valve prosthesis, which is still at this point releasably attached to the catheter delivery system via its commissures, may be driven slightly further downstream into ventricular space to create a greater seating force as between the atrial skirt region and atrial surface of the heart, and to provide additional purchase for any ventricular and/or native leaflet barbs or prongs that may be present in the ventricular skirt region. In embodiments where one or more of the atrial skirt region, the annular region and the ventricular skirt region are covered with a suitable biologic or synthetic prosthetic material, a seal may also be formed between the respective regions of the prosthesis and the associated zone of the native mitral valve apparatus.

Finally, once satisfactory positioning of the prosthesis has been achieved, the commissures are released from the catheter delivery system, allowing the catheter delivery system to be withdrawn, and leaving the mitral valve prosthesis in place as a functional replacement for the native mitral valve apparatus. Upon release of the commissures, the prosthesis may further undergo a final stage of foreshortening and seating as any remaining pressure exerted by the delivery system is relased. The atrial skirt region may recoil slightly from this release in pressure, pulling the prosthesis slightly further up in to the left atrium, and thereby further seating the ventricular skirt region, including any associated barbs, prongs or tabs. In embodiments that comprise trigonal anchoring tabs, the seating thereof pulls the captured anterior leaflet tightly against the prosthesis, thereby avoiding or minimizing obstruction of the Left Ventricular Outflow Tract (LVOT), and firmly seats the ventricular skirt region in the annulus to prevent paravalvular leakage. Once final deployment is complete, the delivery system is retracted and removed.

In a first aspect of the present invention, a method of anchoring a prosthetic valve in a patient's heart comprises providing the prosthetic valve, wherein the prosthetic valve comprises an anchor having an atrial skirt, an annular region, a ventricular skirt, and a plurality of valve leaflets, wherein the anchor has a collapsed configuration for delivery to the heart and an expanded configuration for anchoring with the heart, and positioning the prosthetic valve in the patient's heart. The method also comprises expanding the atrial skirt radially outward so as to lie over a superior surface of the patient's native mitral valve, anchoring the atrial skirt against a portion of the atrium, and radially expanding the annular region of the anchor to conform with and to engage the native mitral valve annulus. The method also comprises radially expanding the ventricular skirt thereby displacing the native mitral valve leaflets radially outward.

At least a portion of the prosthetic valve may be covered with tissue or a synthetic material. Positioning the prosthetic valve may comprise transseptally delivering the prosthetic valve from the right atrium to the left atrium of the heart, or transapically delivering the prosthetic valve from a region outside the heart to the left ventricle of the heart.

Expanding the atrial skirt may comprise slidably moving a restraining sheath away from the atrial skirt thereby allowing radial expansion thereof. The atrial skirt may self-expand when the restraining sheath is removed therefrom. The method may further comprise applying a force on the prosthetic valve to ensure that the atrial skirt engages the superior surface of the mitral valve. The atrial skirt may comprise a plurality of barbs, and expanding the atrial skirt may comprise anchoring the barbs into the superior surface of the mitral valve. Expanding the atrial skirt may comprise sealing the atrial skirt against the superior surface of the native mitral valve.

Radially expanding the annular region may comprise slidably moving a restraining sheath away from the annular region thereby allowing radial expansion thereof. The annular region may self-expand when the restraining sheath is removed therefrom. Radially expanding the annular region may comprise asymmetrically expanding the annular region such that an anterior portion of the annular region is substantially flat, and a posterior portion of the annular region is cylindrically shaped.

The ventricular skirt may further comprise a trigonal anchoring tab on an anterior portion of the ventricular skirt, and radially expanding the ventricular skirt may comprise anchoring the trigonal anchoring tab against a first fibrous trigon on a first side of the anterior leaflet of the native mitral valve. The native anterior leaflet and adjacent chordae tendineae may be captured between the trigonal anchoring tab and an anterior surface of the anchor. The ventricular skirt may further comprise a second trigonal anchoring tab on the anterior portion of the ventricular skirt, and wherein radially expanding the ventricular skirt may comprise anchoring the second trigonal anchoring tab against a second fibrous trigon opposite the first fibrous trigon. The native anterior leaflet and adjacent chordae tendineae may be captured between the second trigonal anchoring tab and an anterior surface of the anchor. The ventricular skirt may further comprise a posterior ventricular anchoring tab on a posterior portion of the ventricular skirt. Radially expanding the ventricular skirt may comprise anchoring the posterior ventricular anchoring tab over a posterior leaflet of the native mitral valve to seat between the posterior leaflet and a ventricular wall of the heart. Radially expanding the ventricular skirt may comprise slidably moving a restraining sheath away from the ventricular skirt thereby allowing radial expansion thereof. The ventricular skirt may self-expand when the restraining sheath is removed therefrom.

The ventricular skirt may comprise a plurality of barbs, and expanding the ventricular skirt may comprise anchoring the barbs into heart tissue. The prosthetic valve may comprise a plurality of prosthetic valve leaflets, and radially expanding the ventricular skirt may comprise displacing the native mitral valve leaflets radially outward thereby preventing interference of the native mitral valve leaflets with the prosthetic valve leaflets. Radially expanding the ventricular skirt may comprise displacing the native mitral valve leaflets radially outward without contacting a ventricular wall, and without obstructing a left ventricular outflow tract. Radially expanding the ventricular skirt may comprise asymmetrically expanding the ventricular skirt such that an anterior portion of the ventricular skirt is substantially flat, and a posterior portion of the ventricular skirt is cylindrically shaped.

The atrial skirt may comprise an alignment element, and the method may comprise aligning the alignment element relative to the patient's valve. The valve may comprise a mitral valve, and aligning may comprise aligning the alignment element with an aortic root and disposing the alignment between two fibrous trigones of an anterior leaflet of the mitral valve. Aligning may comprise rotating the prosthetic valve. The prosthetic valve may comprise a plurality of prosthetic leaflets coupled to one or more commissures, and the method may comprise releasing the commissures from a delivery catheter. The prosthetic valve may comprise a tricuspid leaflet configuration.

The prosthetic valve may have an open configuration in which the prosthetic valve leaflets are disposed away from one another, and a closed configuration in which the prosthetic valve leaflets engage one another. Blood flows freely through the prosthetic valve in the open configuration, and retrograde blood flow across the prosthetic valve is substantially prevented in the closed configuration. The method may comprise reducing or eliminating mitral regurgitation. The prosthetic valve may comprise a therapeutic agent, and the method may comprise eluting the therapeutic agent from the prosthetic valve into adjacent tissue.

In another aspect of the present invention, a prosthetic cardiac valve comprises an anchor having an atrial skirt, an annular region, and a ventricular skirt. The anchor has a collapsed configuration for delivery to the heart and an expanded configuration for anchoring the prosthetic cardiac valve to a patient's heart. The prosthetic valve also comprises a plurality of prosthetic valve leaflets, each of the leaflets having a first end and a free end, wherein the first end is coupled with the anchor and the free end is opposite of the first end. The prosthetic cardiac valve has an open configuration in which the free ends of the prosthetic valve leaflets are disposed away from one another to allow antegrade bloodflow therepast, and a closed configuration in which the free ends of the prosthetic valve leaflets engage one another and substantially prevent retrograde bloodflow therepast.

At least a portion of the atrial skirt may be covered with tissue or a synthetic material. The atrial skirt may further comprise a plurality of barbs coupled thereto, the plurality of barbs adapted to anchor the atrial skirt into a superior surface of the patient's mitral valve. The atrial skirt may comprise a collapsed configuration and an expanded configuration. The collapsed configuration may be adapted for delivery to the patient's heart, and the expanded configuration may be radially expanded relative to the collapsed configuration and adapted to lie over a superior surface of the patient's native mitral valve, thereby anchoring the atrial skirt against a portion of the atrium. The atrial skirt may self-expand from the collapsed configuration to the radially expanded configuration when unconstrained. The atrial skirt may comprise one more radiopaque markers. The atrial skirt may comprise a plurality of axially oriented struts connected together with a connector element thereby forming a series of peaks and valleys. Some of the peaks and valleys may extend axially outward further than the rest of the atrial skirt, thereby forming an alignment element.

At least a portion of the annular region may be covered with tissue or a synthetic material. The annular region may have a collapsed configuration and an expanded configuration. The collapsed configuration may be adapted for delivery to the patient's heart, and the expanded configuration may be radially expanded relative to the collapsed configuration and adapted to conform with and to engage the native mitral valve annulus. The annular region may self expand from the collapsed configuration to the expanded configuration when unconstrained.

The annular region may comprise an asymmetrically D-shaped cross-section having a substantially flat anterior portion, and a cylindrically shaped posterior portion. The annular region may comprise a plurality of axially oriented struts connected together with a connector element thereby forming a series of peaks and valleys. One or more of the axially oriented struts may comprise one or more suture holes extending therethrough, the suture holes sized to receive a suture.

At least a portion of the ventricular skirt may be covered with tissue or a synthetic material. The ventricular skirt may comprise an asymmetrically D-shaped cross-section having a substantially flat anterior portion, and a cylindrically shaped posterior portion. The ventricular skirt may have a collapsed configuration and an expanded configuration. The collapsed configuration may be adapted for delivery to the patient's heart, and the expanded configuration may be radially expanded relative to the collapsed configuration and adapted to displace the native mitral valve leaflets radially outward. The ventricular skirt may self-expand from the collapsed configuration to the expanded configuration when unconstrained.

The ventricular skirt may further comprise a trigonal anchoring tab disposed on an anterior portion of the ventricular skirt. The trigonal anchoring tab may be adapted to being anchored against a first fibrous trigon on a first side of an anterior leaflet of the patient's mitral valve. Thus, the anterior leaflet and adjacent chordae tendineae may be captured between the trigonal anchoring tab and an anterior surface of the anchor. The ventricular skirt may further comprise a second trigonal anchoring tab that may be disposed on the anterior portion of the ventricular skirt. The second trigonal anchoring tab may be adapted to being anchored against a second fibrous trigon opposite the first fibrous trigon, such that the anterior leaflet and adjacent chordae tendineae are captured between the second trigonal anchoring tab and the anterior surface of the anchor. The ventricular skirt may further comprise a posterior ventricular anchoring tab disposed on a posterior portion of the ventricular skirt. The posterior ventricular anchoring tab may be adapted to being anchored over a posterior leaflet of the patient's mitral valve, such that the posterior ventricular anchoring tab is seated between the posterior leaflet and a ventricular wall of the patient's heart. The ventricular skirt may further comprise a plurality of barbs coupled thereto, and that may be adapted to anchor the ventricular skirt into heart tissue. The ventricular skirt may comprise a plurality of struts connected together with a connector element thereby forming a series of peaks and valleys. The one or more struts may comprise one or more suture holes extending therethrough, and that may be sized to receive a suture.

The plurality of prosthetic valve leaflets may comprise a tricuspid leaflet configuration. At least a portion of the one or more prosthetic valve leaflets may comprise tissue or a synthetic material. One or more of the plurality of prosthetic valve leaflets may be disposed over one or more commissure posts or struts that are radially biased inward relative to the ventricular skirt. The one or more commissure posts or struts may comprise one or more suture holes extending therethrough and that may be sized to receive a suture. The one or more prosthetic valve leaflets may be coupled to a commissure post or strut having a commissure tab adapted to releasably engage the commissure post or strut with a delivery device.

The prosthetic cardiac valve may further comprise an alignment element coupled to an anterior portion of the anchor. The alignment element may be adapted to be aligned with an aortic root of the patient's heart and disposed between two fibrous trigones of an anerior leaflet of the patient's mitral valve. The alignment element may be coupled with the atrial skirt. The prosthetic cardiac valve may further comprise a therapeutic agent coupled thereto, and adapted to being controllably eluted therefrom.

In still another aspect of the present invention, a delivery system for delivering a prosthetic cardiac valve to a patient's heart comprises an inner guidewire shaft having a lumen extending therethrough and adapted to slidably receive a guidewire, and a hub shaft concentrically disposed over the inner guidewire shaft. The delivery system also comprises a bell shaft slidably and concentrically disposed over the hub shaft, a sheath slidably and concentrically disposed over the bell shaft, and a handle near a proximal end of the delivery system. The handle comprises an actuator mechanism adapted to advance and retract the bell shaft and the sheath.

The system may further comprise the prosthetic cardiac valve which may be housed in the sheath in a radially collapsed configuration. The prosthetic cardiac valve may comprise an anchor having an atrial skirt, an annular region, and a ventricular skirt. The prosthetic valve may also comprise a plurality of prosthetic valve leaflets. Each of the leaflets may have a first end and a free end. The first end may be coupled with the anchor and the free end may be opposite of the first end. The prosthetic cardiac valve may have an open configuration in which the free ends of the prosthetic valve leaflets are disposed away from one another to allow antegrade bloodflow therepast. The valve may have a closed configuration in which the free ends of the prosthetic valve leaflets engage one another and substantially prevent retrograde blood flow therepast.

Proximal retraction of the sheath relative to the bell shaft may remove a constraint from the prosthetic cardiac valve thereby allowing the prosthetic cardiac valve to self-expand into engagement with the patient's native heart tissue. The prosthetic cardiac valve may be releasably coupled with the hub shaft, and proximal retraction of the bell shaft relative to the hub shaft may release the prosthetic cardiac valve therefrom. The actuator mechanism may comprise a rotatable wheel. The system may further comprise a tissue penetrating distal tip coupled to the hub shaft. The tissue penetrating distal tip may be adapted to pass through and expand an incision in the patient's heart. The system may further comprise a pin lock mechanism releasably coupled with the handle. The pin lock mechanism may limit proximal retraction of the sheath.

These and other embodiments are described in further detail in the following description related to the appended drawing figures.

BRIEF DESCRIPTION OF THE DRAWINGS

In the drawings, like reference numerals designate like or similar steps or components.

FIG. 1 is a schematic illustration of the left ventricle of a heart showing blood flow during systole with arrows.

FIG. 2 is a schematic illustration of the left ventricle of a heart having prolapsed leaflets in the mitral valve.

FIG. 3 is a schematic illustration of a heart in a patient suffering from cardiomyopathy where the heart is dilated and the leaflets do not meet.

FIG. 3A shows, normal closure of the leaflets.

FIG. 3B shows abnormal closure in the dilated heart.

FIG. 4 illustrates mitral valve regurgitation in the left ventricle of a heart having impaired papillary muscles.

FIGS. 5A-5B illustrate the mitral valve.

FIG. 6 illustrates a bottom, partial cross-sectional view of an exemplary prosthetic mitral valve.

FIG. 7 is a perspective view of the anchor portion of the prosthetic mitral valve seen in FIG. 6.

FIG. 8A is a perspective view of a prosthetic mitral valve.

FIG. 8B is a top view from the atrium of the prosthetic valve in FIG. 8A.

FIG. 9A illustrates a perspective view of the prosthetic valve in FIG. 8A from the atrium.

FIG. 9B illustrates a perspective view of the prosthetic valve in FIG. 8A from the ventricle.

FIG. 10 illustrates the prosthetic valve of FIG. 8A uncovered and unrolled in a flat pattern.

FIG. 11 is a side view of a delivery device for implantation of a prosthetic valve.

FIG. 12 is a perspective exploded view of a proximal portion of the delivery device in FIG. 11.

FIG. 13 is a perspective exploded view of a distal portion of the delivery device in FIG. 11.

FIG. 14 is a cross-section of the a proximal portion of the delivery device in FIG. 11.

FIGS. 15A-15C are cross-sectional views of a distal portion of the delivery device in FIG. 11.

FIG. 16 is a side view of another exemplary embodiment of a delivery device for implantation of a prosthetic valve.

FIG. 17 is a perspective view of the delivery device in FIG. 16.

FIG. 18 is a perspective exploded view of the delivery device in FIG. 16.

FIGS. 19A-19B are side views of the delivery device in FIG. 16 during various stages of operation.

FIG. 20 illustrates a distal portion of the delivery device in FIG. 16 that is adapted to engage a portion of a prosthetic valve.

FIG. 21 illustrates engagement of the delivery device in FIG. 16 with the prosthetic valve of FIG. 8A.

FIGS. 22A-22G illustrate an exemplary method of transapically delivering a prosthetic mitral valve.

FIGS. 23A-23G illustrate an exemplary method of transseptally delivering a prosthetic mitral valve.

FIG. 24 illustrates a prosthetic mitral valve implanted in the mitral space.

FIG. 25 illustrates a bottom view of a mitral valve implanted in the mitral space looking upward from the left ventricle.

DETAILED DESCRIPTION OF THE INVENTION

Specific embodiments of the disclosed device, delivery system, and method will now be described with reference to the drawings. Nothing in this detailed description is intended to imply that any particular component, feature, or step is essential to the invention.

Cardiac Anatomy. The left ventricle LV of a normal heart H in systole is illustrated in FIG. 1. The left ventricle LV is contracting and blood flows outwardly through the aortic valve AV, a tricuspid valve in the direction of the arrows. Back flow of blood or “regurgitation” through the mitral valve MV is prevented since the mitral valve is configured as a “check valve” which prevents back flow when pressure in the left ventricle is higher than that in the left atrium LA. The mitral valve MV comprises a pair of leaflets having free edges FE which meet evenly to close, as illustrated in FIG. 1. The opposite ends of the leaflets LF are attached to the surrounding heart structure along an annular region referred to as the annulus AN. The free edges FE of the leaflets LF are secured to the lower portions of the left ventricle LV through chordae tendineae CT (also referred to herein as the chordae) which include a plurality of branching tendons secured over the lower surfaces of each of the valve leaflets LF. The chordae CT in turn, are attached to the papillary muscles PM which extend upwardly from the lower portions of the left ventricle and interventricular septum IVS.

Referring now to FIGS. 2-4, a number of structural defects in the heart can cause mitral valve regurgitation. Ruptured chordae RCT, as shown in FIG. 2, can cause a valve leaflet LF2 to prolapse since inadequate tension is transmitted to the leaflet via the chordae. While the other leaflet LF1 maintains a normal profile, the two valve leaflets do not properly meet and leakage from the left ventricle LV into the left atrium LA will occur, as shown by the arrow.

Regurgitation also occurs in the patients suffering from cardiomyopathy where the heart is dilated and the increased size prevents the valve leaflets LF from meeting properly, as shown in FIG. 3. The enlargement of the heart causes the mitral annulus to become enlarged, making it impossible for the free edges FE to meet during systole. The free edges of the anterior and posterior leaflets normally meet along a line of coaptation C as shown in FIG. 3A, but a significant gap G can be left in patients suffering from cardiomyopathy, as shown in FIG. 3B.

Mitral valve regurgitation can also occur in patients who have suffered ischemic heart disease where the functioning of the papillary muscles PM is impaired, as illustrated in FIG. 4. As the left ventricle LV contracts during systole, the papillary muscles PM do not contract sufficiently to effect proper closure. The leaflets LF1 and LF2 then prolapse, as illustrated. Leakage again occurs from the left ventricle LV to the left atrium LA, as shown by the arrow.

FIG. 5A more clearly illustrates the anatomy of a mitral valve MV which is a bicuspid valve having an anterior side ANT and a posterior side POST. The valve includes an anterior (aortic) leaflet AL and a posterior (mural) leaflet PL. Chordae tendineae CT couple the valve leaflets AL, PL with the antero-lateral papillary muscle ALPM and the postero-medial papillary muscle PMPM. The valve leaflets AL, PL join one another along a line referred to as the antero-lateral commissure ALC and the posterior-medial commissure PMC. The annulus AN circumscribes the valve leaflets, and two regions adjacent an anterior portion of the annulus, on opposite sides of the anterior leaflet are referred to as the left fibrous trigone LFT and also the right fibrous trigone RFT. These areas are indicted by generally by the solid triangles. FIG. 5B more clearly illustrates the left and right fibrous trigones, LFT, RFT.

While various surgical techniques as well as implantable devices have been proposed and appear to be promising treatments for mitral regurgitation, surgical approaches can require a lengthy recovery period, and implantable devices have varying clinical results. Therefore, there still is a need for improved devices and methods for treating mitral regurgitation. While the embodiments disclosed herein are directed to an implantable prosthetic mitral valve for treating mitral regurgitation, one of skill in the art will appreciate that this is not intended to be limiting, and the device and methods disclosed herein may also be used to treat other cardiac valves such as the tricuspid valve, aortic valve, pulmonary valve, etc, as well as other valves in the body such as venous valves.

Prosthetic Valve. Prosthetic valves have been surgically implanted in the heart as a treatment for mitral regurgitation. Some of these valves have been valves harvested from animals such as porcine valves, and others have been prosthetic mechanical valves with or without a tissue covering. More recently, minimally invasive catheter technology has been used to deliver prosthetic valves to the heart. These valves typically include an anchor for securing the valve to the patient's heart, and a valve mechanism, either a mechanical valve, a valve with animal tissue, or combinations thereof. The prosthetic valve once implanted, takes over for malfunctioning native valve, thereby reducing or eliminating valvar insufficiency. While some of these valves appear promising, there still is a need for improved valves. The following discloses exemplary embodiments of a prosthetic valve, a delivery system for the prosthetic valve, and methods of delivering the valve that overcome some of the challenges associated with existing prosthetic valves.

Referring now to FIGS. 6-7, exemplary embodiments of a mitral valve prosthesis generally designated with reference numeral 10 comprise tricuspid tissue-type prosthetic one-way valve structure 12 comprising leaflets 14 affixed within self-expanding or expandable anchor portion 16 having a geometry that expands into low profile atrial skirt region 18, annular region 20, ventricular skirt region 22, and a plurality of leaflet commissures 24 (also referred to herein as commissure posts) extending axially in a cantilevered fashion downstream into the sub-annular space defined by ventricular skirt region 22. FIG. 6 shows a partial cross-section of the valve 10 from the patient's left ventricle looking upward toward the right atrium. The atrial skirt region 18 is anchored to a lower portion of the right atrium 19. The valve leaflets 14 have an open position (not illustrated) and a closed position illustrated in FIG. 6. In the open position, the leaflets 14 are displaced away from one another to allow blood flow therepast, and in the closed position, the leaflets 14 engage one another to close the valve and prevent retrograde blood flow therepast. The valve commissures 24 may be configured to optimize the efficiency of the prosthetic valve structure 12 and the load distribution on the leaflets 14 by providing for the attachment of the leaflets 14 along arcuate seams 28 (best seen in FIG. 7), and by being made selectively flexible at different points or zones along their axial length through the addition/deletion of reinforcing struts.

FIG. 7 shows a perspective view of the anchor portion 16 of the valve 10 which has been formed from a series of interconnected struts. The atrial skirt region 18 forms an annular flanged region on the anchor to help secure an upper portion of the prosthetic valve in the atrium, and the annular region 20 is a cylindrical region for anchoring the valve along the native valve annulus. The ventricular skirt region 22 similarly is cylindrically shaped and helps anchor a lower portion of the valve in the patient's left ventricle. Any portion, or all of the anchor may be covered with tissue such as pericardium or other tissues disclosed herein, or a synthetic material such as Dacron or ePTFE may be used to cover the anchor. The covering helps to seal the anchor to the native valve, and this helps funnel blood into and through the prosthetic valve, rather than around the valve. In some embodiments, the anchor may remain uncovered. The prosthetic valve has an expanded configuration and a collapsed configuration. The collapsed configuration has a low profile cylindrical shape that is suitable for mounting on a delivery system and delivery is preferably made either transluminally on a catheter, or transapically through the heart wall. The expanded configuration (as illustrated) allow the prosthetic valve to be anchored into a desired position.

FIG. 8A illustrates a perspective view of a preferred embodiment of a prosthetic mitral valve with optional coverings removed to allow visibility of the anchor struts. FIG. 8B illustrates a top view of the prosthetic valve in FIG. 8A from the atrium looking down into the ventricle. The valve 800 includes an asymmetrical expanded anchor portion having a D-shaped cross-section. As shown, the anchor portion generally comprises anterior 802 and posterior 804 aspects along the longitudinal axis thereof, as well as atrial 806, annular 808 and ventricular 810 regions that correspond generally to the atrial skirt 18, annular 20 and ventricular skirt 22 regions of the embodiment described above in FIGS. 6-7. Commissures (also referred to herein as commissure posts) 813 also correspond generally to the leaflets 14 of the embodiment in FIGS. 6-7. The prosthetic valve 800 has a collapsed configuration and an expanded configuration. The collapsed configuration is adapted to loading on a shaft such as a delivery catheter for transluminal delivery to the heart, or on a shaft for transapical delivery through the heart wall. The radially expanded configuration is adapted to anchor the valve to the patient's native heart adjacent the damaged valve. In order to allow the valve to expand from the collapsed configuration to the expanded configuration, the anchor portion of the valve may be fabricated from a self-expanding material such as a nickel titanium alloy like nitinol, or it may also be made from spring temper stainless steel, or a resilient polymer. In still other embodiments, the anchor may be expandable with an expandable member such as a balloon. In preferred embodiments, the anchor is fabricated by laser cutting, electrical discharge machining (EDM), or photochemically etching a tube. The anchor may also be fabricated by photochemically etching a flat sheet of material which is then rolled up with the opposing ends welded together.

The atrial skirt portion 816 forms a flanged region that helps to anchor the prosthetic valve to the atrium, above the mitral valve. The atrial skirt includes a plurality of triangular fingers which extend radially outward from the anchor to form the flange. The posterior 804 portion of the atrial skirt 816 is generally round or circular, while a portion of the anterior 802 part of the atrial skirt 816 is flat. Thus, the atrial skirt region preferably has a D-shaped cross-section. This allows the prosthetic valve to conform to the patient's cardiac anatomy without obstructing other portions of the heart, as will be discussed below. Each triangular finger is formed from a pair of interconnected struts. The triangular fingers of the atrial skirt generally are bent radially outward from the central axis of the prosthetic valve and lie in a plane that is transverse to the valve central axis. In some embodiments, the atrial skirt lies in a plane that is substantially perpendicular to the central axis of the valve. The anterior portion 802 of the atrial skirt 806 optionally includes an alignment element 814 which may be one or more struts which extend vertically upward and substantially parallel to the prosthetic valve. The alignment element 814 may include radiopaque markers (not illustrated) to facilitate visualization under fluoroscopy. The alignment element helps the physician to align the prosthetic valve with the native mitral valve anatomy, as will be discussed later.

Disposed under the atrial skirt region is the annular region 820 which also has a collapsed configuration for delivery, and an expanded configuration for anchoring the prosthetic valve along the native valve annulus. The annular region is also comprised of a plurality of interconnected struts that form a series of cells, preferably closed. Suture holes 821 in some of the struts allow tissue or other coverings (not illustrated) to be attached to the annular region. Covering all or a portion of the anchor with tissue or another covering helps seal the anchor against the heart valve and adjacent tissue, thereby ensuring that blood is funneled through the valve, and not around it. The annular region may be cylindrical, hut in preferred embodiments has a posterior portion 804 which is circular, and an anterior portion 802 which is flat, thereby forming a U-shaped cross-section. This D-shaped cross-section conforms better to the native mitral valve anatomy without obstructing blood flow in other areas of the heart.

The lower portion of the prosthetic valve includes the ventricular skirt region 828. The ventricular skirt region also has a collapsed configuration for delivery, and an expanded configuration for anchoring. It is formed from a plurality of interconnected struts that form a series of cells, preferably closed, that can radially expand. The ventricular skirt in the expanded configuration anchors the prosthetic valve to the ventricle by expanding against the native mitral valve leaflets. Optional barbs 823 in the ventricular skirt may be used to further help anchor the prosthetic valve into the ventricular tissue. Barbs may optionally also be included in the atrial skirt portion as well as the annular region of the anchor. Additionally, optional suture holes 821 in the ventricular skirt may be used to help suture tissue or another material to the ventricular skirt region, similarly as discussed above. The anterior 802 portion of the ventricular skirt may be flat, and the posterior 804 portion of the ventricular skirt may be circular, similarly forming a D-shaped cross-section to anchor and conform to the native anatomy without obstructing other portions of the heart. Also, the lower portions of the ventricular skirt serve as deployment control regions since the lower portions can remain sheathed thereby constraining the ventricular skirt from radial expansion until after the optional ventricular trigonal tabs and posterior tab have expanded, as will be explained in greater detail below.

The ventricular skirt portion may optionally also include a pair of ventricular trigonal tabs 824 on the anterior portion of the anchor (only 1 visible in this view) for helping to anchor the prosthetic valve as will be discussed in greater detail below. The ventricular skirt may also optionally include a posterior tab 826 on a posterior portion 804 of the ventricular skirt for anchoring the prosthetic valve to a posterior portion of the annulus. The trigonal tabs 824 or the posterior tab 826 are tabs that extend radially outward from the anchor, and they are inclined upward in the upstream direction.

The actual valve mechanism is formed from three commissures posts (also referred to as commissures) 813 which extend radially inward toward the central axis of the anchor in a funnel or cone-like shape. The commissures 813 are formed from a plurality of interconnected struts that create the triangular shaped commissures. The struts of the commissures may include one or more suture holes 821 that allow tissue or a synthetic material to be attached to the commissures. In this exemplary embodiment, the valve is a tricuspid valve, therefore it includes three commissures 813. The tips of the commissures may include a commissure tab 812 (also referred to as a tab) for engaging a delivery catheter. In this embodiment, the tabs have enlarged head regions connected to a narrower neck, forming a mushroom-like shape. The commissures may be biased in any position, but preferably angle inward slightly toward the central axis of the prosthetic valve so that retrograde blood flow forces the commissures into apposition with one another to close the valve, and antegrade blood flow pushes the commissures radially outward, to fully open the valve. FIG. 8B is a top view illustrating the prosthetic valve of FIG. 8A from the atrial side, and shows the preferred D-shaped cross-section.

FIG. 9A illustrates the prosthetic mitral valve of FIGS. 8A-8B with a covering 870 coupled to portions of the anchor with suture 872. This view is taken from an atrial perspective. In this embodiment, the covering is preferably pericardium which may come from a number of sources as disclosed elsewhere in this specification. In alternative embodiments, the covering may be a polymer such as Dacron polyester, ePTFE, or another synthetic material. The covering is preferably disposed over the annular region 820 and the ventricular skirt region 828, and in some embodiments the anterior ventricular trigonal 824 tabs and the ventricular posterior tab 830 may also be covered with the same or a different material. The covering helps seal the anchor against the adjacent tissue so that blood funnels through the valve mechanism. In this embodiment, the atrial skirt is left uncovered, as well as tabs 824, 830. Additionally, radiopaque markers 814a form a portion of the alignment element and facilitate visualization of the prosthetic valve under fluoroscopy which is important during alignment of the valve.

FIG. 9B is a perspective view of the prosthetic mitral valve seen in FIG. 9A, as seen from the ventricle. The struts of the valve commissures are covered with the same material or a different material as the annular and ventricular regions as discussed above, thereby forming the tricuspid valve leaflets 813. FIG. 9B shows the valve in the closed configuration where the three leaflets are engaged with one another preventing retrograde blood flow. Commissure tabs 812 remain uncovered and allow the commissures to be coupled with a delivery device as will be explained below. The prosthetic valve in FIGS. 9A-9B may be sterilized so they are suitable for implantation in a patient using methods known in the art.

FIG. 10 illustrates the prosthetic valve of FIG. 9A with the covering removed, and the remaining anchor unrolled and flattened out. The prosthetic valve 800 is formed from a plurality of interconnected struts. For example, the atrial skirt region 806 includes a plurality of interconnected struts that form a series of peaks and valleys. The flat anterior region 802 of the prosthetic valve has its peaks and valleys axially offset from those of the remaining portion of the atrial skirt, and this region becomes a part of the alignment element 814. Radiopaque markers 814a are disposed on either side of the offset peaks and valleys and help with visualization during implantation of the valve. An axially oriented connector joins the struts of the skirt region 806 with the struts of the annular region 808. The annular region is also comprised of a plurality of axially oriented and interconnected struts that form peaks and valleys. Connector struts couple struts of the annular region with the struts of the ventricular region 810. The ventricular region also includes a plurality of interconnected struts that form peaks and valleys. Additionally, the struts form the leaflet commissures 813, the ventricular skirt 828, as well as the trigonal and posterior tabs 824, 830. Suture holes 821 are disposed along the struts of the annular region as well as the ventricular region to allow attachment of a cover such as pericardium or a polymer such as Dacron or ePTFE. Barbs 823 are disposed along the ventricular skirt 828 to help anchor the prosthetic valve to adjacent tissue. Commissure tabs or tabs 812 are disposed on the tips of the commissures 813 and may be used to releasably couple the prosthetic valve with a delivery system as will be described below. One of skill in the art will appreciate that a number of strut geometries may be used, and additionally that strut dimensions such as length, width, thickness, etc. may be adjusted in order to provide the anchor with the desired mechanical properties such as stiffness, radial crush strength, commissure deflection, etc. Therefore, the illustrated geometry is not intended to be limiting.

Once the flat anchor pattern has been formed by EDM, laser cutting, photochemical etching, or other techniques known in the art, the anchor is radially expanded into a desired geometry. The anchor is then heat treated using known processes to set the shape. Thus, the anchor may be loaded onto a delivery catheter in a collapsed configuration and constrained in the collapsed configuration with a constraining sheath. Removal of the constraining sheath will allow the anchor to self-expand into its unbiased pre-set shape. In other embodiments, an expandable member such as a balloon may be used to radially expand the anchor into its preferred expanded configuration.

Delivery Systems. FIGS. 11-45C show a delivery apparatus 1124 fashioned to deliver a prosthetic mitral valve to the heart transapically. However, one of skill in the art will appreciate that the delivery system may be modified and relative motion of the various components adjusted to allow the device to be used to deliver a prosthetic mitral valve transseptally. The delivery apparatus is generally comprised of a handle 1101 that is the combination of a handle section 1102 and a handle section 1103 (best seen in FIG. 12), as well as a flexible tip 1110 that can smoothly penetrate the apex of the heart, and a sheath catheter 1109 which houses several additional catheters that are designed to translate axially and will be described in detail below.

The handle 1101 includes a female threaded luer adaptor 1113 which connects to a Tuohy Borst adaptor 1114 in order to provide a hemostatic seal with a 0.035″ diameter guide wire (not shown). The female threaded luer adaptor 1113 is in threaded contact with the proximal section of the handle 1101 through a threaded port 1131 (best seen in FIG. 12).

As can be seen in FIG. 11, the handle 1101 provides location for the control mechanisms used to position and deploy a prosthetic mitral valve. The handle 1101 provides housing for a thumbwheel 1106 that can be accessed through a window 1137 that appears on both the top and bottom of the handle 1101. The thumbwheel 1106 internally mates with a threaded insert 1115 (best seen in FIG. 12) that actuates the sheath catheter 1109, and the mechanics of this interaction will be explained in detail below.

FIG. 11 also shows a deployment thumbwheel 1104 that provides linear translation to a deployment catheter 1120 (best seen in FIG. 12) when turned, since the turning motion of the deployment thumbwheel 1104 acts as a power screw, pushing the peg 1128 forward and distally from the user. The mechanics behind the peg 1128 will be further detailed below. The thumbwheel lock 1105 provides a security measure against unwanted rotation of the deployment thumbwheel 1104 by acting as a physical barrier to rotation. In order to turn the deployment thumbwheel 1104 the user must push forward the thumbwheel lock 1105, disengaging it from two slots 1147 (seen in FIG. 12) in the deployment thumbwheel 1105.

As can also be seen in FIG. 11, a bleed valve 1108 and fluid line 1107 are connected to an internal mechanism in the distal portion of the handle 1101, which provides a hemostatic seal for the sheath catheter 1109. The details of this connection will be described below.

Internal mechanics of the delivery apparatus 1124 are illustrated in detail in FIG. 12, and the following descriptions will reveal the interactions between individual components, and the manner in which those components combine in order to achieve a prosthetic heart valve delivery apparatus.

As seen in FIG. 12, a handle section 1103 and handle section 1102 combine to create a handle 1101 that forms the basis of the delivery apparatus 1124. In order to advance the sheath catheter 1109 during valve loading, or retract the sheath catheter 1109 during deployment, a rotatable thumbwheel 1106 is in threaded contact (internal threads 1129 seen in FIG. 14) with a threaded insert 1115 (external threads 1130 of FIG. 13) that translates linearly along the axis of the delivery apparatus, from a proximal position to a distal position. The sheath catheter 1109 is in mating contact with the threaded insert 1115 and is fastened through the use of a collar 1117 that aligns and mates the collar with the insert. The collar 1117 is fastened with screws 1116 (best seen in DETAIL A in FIG. 14) to the threaded insert 1115 and contains a fluid port 1142 (best seen in DETAIL A in FIG. 14) that provides location for the fluid line 1117 so that hemostasis can be maintained between the patient and delivery apparatus. An O-ring 1118 (best seen in DETAIL A in FIG. 14) seals the stationary catheter 1119 (best seen in FIG. 14) against the sheath catheter 1109. The fluid line 1107 also provides a means of visually locating the sheath catheter 1109 with respect to position, as a slot 1138 in the handle 1101 allows the fluid line 1107 to translate with the sheath catheter 1109 (through a hole 1151 (best seen in DETAIL A in FIG. 14) during operation, and this translation is highly visible. In order to prevent rotation of the threaded insert during translation, a flat face 1164 has been machined onto both sides of the threaded insert 1115. The flat faces 1164 remain in contact with bosses 1139 and 1140 that are located on both handle section 1102 and handle section 1103 so that the bosses 1139 and 1140 act to grip the threaded insert 1115 and prevent rotation. A textured pattern 1155 allows the user to easily turn the thumbwheel 1106 in the surgical field. Detents 1141 (best seen in FIG. 14) locate flanges 63 (seen in FIG. 14) on the thumbwheel 1116 in order to allow for rotation.

The manner in which individual catheters (there are four catheters) move with respect to each other is illustrated in FIG. 12. Sheath catheter 1109 provides housing for the stationary catheter 1119, which in turn provides housing for the movable hub catheter 1120. The hub catheter 1120 translates linearly with respect to the nose catheter 1121 which can also be translated with respect to each previous catheter, and the handle 1101. The stationary catheter 1119 is mated to a handle section 1103 in an internal bore 1150 which also forms a seal between the stationary catheter 1119 and the hub catheter 1120. The distal portion of the stationary catheter 1119 is formed in the shape of a bell 1122 (see DETAIL A in FIG. 15A) which acts as a housing to retain the hub capture 1123 (seen in DETAIL A in FIG. 15A).

As previously stated a thumbwheel lock 1105 prevents rotation of the deployment thumbwheel 1104. In order to provide a seating force that keeps the thumbwheel lock 1105 in a locked position until manipulated, a spring 1125 is housed in an internal bore 62 (best seen in FIG. 14) and abuts against a shoulder 1161 (best seen in FIG. 14) that is located inside the thumbwheel lock 1105. This spring 1125 maintains the leading edge 1149 of the thumbwheel lock 1105 in a locked position within the two slots 1147 of the deployment thumbwheel 1104. Gripping texture 1151 is provided on the thumbwheel lock 1105 for ease of use. In order to locate and retain the thumbwheel lock 1105 inside of the handle 1101, a slot 1135 has been provided in both a handle section 1102 and a handle section 1103.

As shown in FIG. 12, a sliding block 1127 is housed inside of flat parallel faces 1134 which appear on the inside of the handle 1101. This sliding block 1127 is in mating contact with hub catheter 1120 and is the physical mechanism that linearly actuates the catheter. A spring 1126 is mounted on an external post 1159 and abuts against a shoulder 1133 that is located on the distal end of the sliding block 1127. This spring 1126 forces a peg 1128 (located inside a thru-hole 1156 of FIG. 14) into contact with the proximal edge of an angled slot 1148 that is cut into the deployment thumbwheel 1104. The deployment thumbwheel 1104 is contained between a shoulder 1136 and a snap ring (not shown), both of which are features of the handle 1101. Gripping texture 1153 on the deployment thumbwheel 1104 allows the user to easily rotate the thumbwheel in a clockwise direction, actuating the peg 1128 to ride distally along the slot 1148 and move the sliding block 1127, which pushes the hub catheter 1120 and hub 1123 (best seen in DETAIL A of FIG. 15A) forward and out of the bell 1122 (seen in DETAIL A of FIG. 15A). A slot 1132 appears in a handle section 1102 and a handle section 1103 and prevents the peg 1128 from translating beyond a desired range.

A nose catheter 1121 extends from a Tuohy Borst adaptor 1114 on the proximal end of the handle 1101, and internally throughout the handle and the respective catheters (sheath catheter 1109, stationary catheter 1119, and hub catheter 1120), terminating inside the rigid insert 1112 (seen in FIG. 15A) of the flexible tip 1110 (seen in FIG. 15A) that abuts with the distal end of the sheath catheter 1109.

FIG. 13 displays an exploded view of the tip section of the delivery apparatus 1124, and shows the relation between prosthetic mitral valve 1165 and the internal and external catheters. When crimped and loaded, the prosthetic mitral valve 1165 is encased between the internal surface of the sheath catheter 1109 and the external surface of the nose catheter 1121. In order to capture and anchor the prosthetic mitral valve 1165 within the delivery apparatus 1124, three commissure tabs 1160 (circumferentially spaced at 120° apart) appearing on the proximal end of the prosthetic mitral valve 1165 provide points of contact between the valve and three slots 1143 (seen in FIG. 15A) that are machined into the outer surface of the hub 1123 (circumferentially spaced at 120° apart). After first advancing the hub catheter 1120 (FIG. 15A) by rotating the deployment thumbwheel 1104 (seen in FIG. 12) clockwise, the three commissure tabs 1160 can be captured within the three slots 1143 (seen in FIG. 15A). The hub 1123 can then be retracted into the bell 1122 by releasing the deployment thumbwheel 1104 (seen in FIG. 12). In this position the prosthetic mitral valve 1165 is anchored to the delivery apparatus 1124, and further crimping of the valve will allow the sheath catheter 1109 to be advanced over the valve.

FIGS. 15A-15C further detail the manner in which loading of the prosthetic mitral valve 1165 (seen in FIG. 13) into the delivery apparatus 1124 can be achieved. Initially, the flexible tip 1110 is abutted against the distal edge 1157 of the sheath catheter 1109. The flexible tip 1110 is comprised of a rigid insert 1112, and a soft and flexible tip portion 1111 which is over-molded onto the rigid insert 1112. The shoulder 1145 and tapered face 1146 of the rigid insert 1112 act to guide and locate the distal edge 1157 of the sheath catheter 1109, so that the catheter may rest against and be stiffened by the flexible tip 1110, and be more easily introduced into the apex of the heart.

An initial position from which loading can be achieved is illustrated in FIG. 15A. As a first step in the loading of a prosthetic mitral valve 1165 (seen in FIG. 13) into the delivery apparatus 1124, the sheath catheter 1109 is withdrawn by rotation of the thumbwheel 1106 in a clockwise direction. The distal edge 1157 of the sheath catheter 1109 is retracted until it passes the distal edge of the bell 1122, as illustrated in DETAIL A of FIG. 15B. As a second step in the loading of a prosthetic mitral valve 1165 (seen in FIG. 13) into the delivery apparatus 1124, the hub 1123 is advanced from beneath the bell 1122 by clockwise turning of the deployment thumbwheel 1104 (seen in FIG. 12), as illustrated in DETAIL A of FIG. 15C. The deployment thumbwheel may only be turned once the thumbwheel lock 1105 (see FIG. 12) has been set in the forward position, disengaging it from contact with the thumbwheel. Advancement of the hub 1123 uncovers three slots 1143 into which three commissure tabs 1160 of the prosthetic mitral valve 1165 (seen in FIG. 13) will fit and be anchored. After anchoring of the commissure tabs 1160 into the slots 1143 by retraction of the hub 1123 has been achieved, a third step in the loading of a prosthetic mitral valve 1165 (seen in FIG. 13) into the delivery apparatus 1124 may be performed. The prosthetic mitral valve 1165 (seen in FIG. 13) can be crimped down to a minimum diameter by a loading mechanism (not shown), and then the sheath cannula 1109 can be advanced forward so as to cover the valve, by rotation of the thumbwheel 1106 in a counter-clockwise direction. The delivery apparatus 1124 and prosthetic mitral valve 1165 are then ready for deployment.

FIGS. 16-19B illustrate another exemplary embodiment of a delivery device for implanting a prosthetic valve in the heart transapically. However, one of skill in the art will appreciate that the delivery system may be modified and relative motion of the various components adjusted to allow the device to be used to deliver a prosthetic transseptally. The delivery apparatus is generally comprised of a handle 1601 that is the combination of two halves (1610 and 1635), as well as a tip 1603 that can smoothly penetrate the apex of the heart, and a flexible sheath 1602 which is comprised of concentric catheters that are designed to translate axially and will be described in detail below.

The handle 1601 includes a handle cap 1611 which connects to a female threaded luer adaptor 1612 in order to provide a sealable exit for a 0.035″ diameter guide-wire (not shown). The handle cap 1611 is attached to the handle 1601 with threaded fasteners 1613. The female threaded luer adaptor 1612 is in threaded contact with the handle cap 1611 through a tapped port, and when fully inserted squeezes against an o-ring (1636 best seen in FIG. 18) which seals against the outer diameter of a guide-wire catheter (1621 best seen in FIG. 18).

As can be seen in FIG. 17, the handle 1601 provides location for the control mechanisms used to position and deploy a prosthetic mitral valve. The handle 1601 provides housing for a thumbwheel 1616 that can be accessed through a window 1606 that appears on both the top and bottom of the handle 1601. The thumbwheel 1616 internally mates with a threaded insert (1627 in FIG. 18) that actuates the sheath catheter 1604, and the mechanics of this interaction will be explained in detail below.

FIG. 17 also shows a first hemostasis tube 1617 that is inserted internally through a slot 1605, and that mates with a first hemp-port through a hole (1625 and 1626 in FIG. 18 respectively). The first hemostasis tube 1617 allows for fluid purging between internal catheters. The position of the first hemostasis tube 1617 along the slot 1605 provides a visual cue as to the position of the sheath catheter 1604, and relative deployment phase of a prosthetic mitral valve (not shown). The relationship between the connection of the first hemostasis tube 1617 and the sheath catheter 1604 will be described below.

As can also be seen in FIG. 17, a second hemostasis tribe 1614 is inserted into the handle 1601 and mated to a second hemo-port (1629 in FIG. 18) in order to allow fluid purging between internal catheters, and details of this insertion will be described below. Finally, a pin lock 1608 provides a security measure against premature release of a prosthetic mitral valve, by acting as a physical barrier to translation between internal mechanisms. Pin lock prongs 1615 rely on spring force to retain the pin lock 1608 in the handle 1601, and a user must first pull out the pin lock 1608 before final deployment of a prosthetic valve.

FIG. 17 also shows how the handle 1601 is fastened together by use of threaded fasteners and nuts (1607 and 1639 of FIG. 18 respectively), and countersunk locator holes 1609 placed throughout the handle length.

Internal mechanisms of the delivery system are illustrated in detail in FIG. 18, and the following descriptions will reveal the interactions between individual components, and the manner in which those components combine in order to create a system that is able to deliver a prosthetic mitral valve preferably transapically.

As seen in FIG. 18, the flexible sheath 1602 is comprised of four concentrically nested catheters. In order from smallest to largest in diameter, the concentrically nested catheters will be described in detail. The innermost catheter is a guide-wire catheter 1621 that runs internally throughout the entire delivery system, beginning at the tip 1603 and terminating in the female threaded luer adaptor 1612. The guide-wire catheter 1621 is composed of a lower durometer, single lumen Pebax extrusion and is stationary. It provides a channel through which a guide-wire (not shown) can communicate with the delivery system. The next catheter is the hub catheter 1622 which provides support for the hub 1620 and is generally comprised of a higher durometer, single lumen PEEK extrusion. The hub catheter 1622 is in mating connection with both the hub 1622 at the distal end, and a stainless steel support rod 1634 at the proximal end. The stainless steel support rod 1634 is held fixed by virtue of a stopper 1637 that is encased in the handle 1601. The hub catheter 1622 is stationary, and provides support and axial rigidity to the concentrically nested catheters. The next catheter is the bell catheter 1624, which provides housing to the hub 1620 and is generally comprised of a medium durometer, single lumen Pebax extrusion, including internal steel braiding and lubricious liner, as well as a radiopaque marker band (not shown). The bell catheter 1624 translates axially, and can be advanced and retracted with respect to the hub 1620. The bell catheter 1624 is in mating connection with the second Nemo-port 1629 at the proximal end, and hemostasis between the bell catheter 1624 and the stainless steel support rod 1634 can be achieved by purging the second hemostasis tube 1614. The bell catheter 1624 is bumped up to a larger diameter 1623 on the distal end in order to encapsulate the hub 1620. The outermost and final catheter is the sheath catheter 1604 which provides housing for a prosthetic mitral valve (not shown), and which is able to penetrate the apex of the heart (not shown), by supporting and directing a tip 1603 and assisting in the dilation of an incision in the heart wall muscle. The sheath catheter 1604 is generally comprised of a medium durometer, single lumen Pebax extrusion, including internal steel braiding and lubricious liner, as well as radiopaque marker band (not shown). The sheath catheter 1604 translates axially, and can be advanced and retracted with respect to the hub 1620. The sheath catheter 1604 is in mating connection with the first hemo-port 1625 at the proximal end, and hemostasis between the sheath catheter 1604 and the bell catheter 1624 can be achieved by purging the first hemostasis tube 1617.

As seen in FIG. 18, the proximal end of the sheath catheter 1604 is in mating contact with a first hemo-port 1625. The first hemo-port is in mating contact with a threaded insert 1627, and an o-ring 1638, which is entrapped between the first hemo-port 1625 and the threaded insert 1627 in order to compress against the bell catheter 1624, creating a hemostatic seal. As the thumbwheel 1616 is rotated, the screw insert 1627 will translate, and the sheath catheter 1624 can be retracted or advanced by virtue of attachment. In order to provide adequate stiffness to dilate heart wall tissue, the distal edge of the sheath catheter 1604 will abut against a shoulder 1618 located on the tip 1603. This communication allows the tip 1603 to remain secure and aligned with the sheath catheter 1604 during delivery, and creates piercing stiffness.

FIG. 18 also details the mechanism through which the bell catheter 1624 can be retracted or advanced with respect to the hub 1620. The thumbwheel 1616 can be rotated to such an extent that the screw insert 1627 will be brought into contact with two pins 1628 that are press fit into the second Nemo-port 1629. As the bell catheter 1624 is in mating contact with the second hemp-port 1629, further rotation of the thumbwheel 1616 will cause the second hemo-port 1629 to translate and press against a spring 1633 by virtue of connection to a second hemo-port cap 1632. This advancement will cause the bumped larger diameter section 1623 of the bell catheter 1624 to be retracted from the hub 1620. As the thumbwheel 1616 is rotated in the opposite direction, restoring force produced by the spring 1633 will cause the second Nemo-port 1629 to be pushed in the opposite direction, drawing the bumped larger diameter section 1623 of the bell catheter 1624 back over the hub 1620, an action that is necessary during the initial loading of a valve prosthesis.

FIG. 18 further details the manner in which hemostasis is achieved between the stainless steel support rod 1634 and the bell catheter 1624. An O-ring 1631 is compressed between the second hemp-port 1629 and the second hemp-port cap 1632, creating a seal against the stainless steel support rod 1634. Hemostasis between the bell catheter 1624 and the stainless steel support rod 1634 can be achieved by purging the second hemostasis tube 1614, which is in communication with the void to be purged through a slot and hole 1630.

The deployment process and actions necessary to activate the mechanisms responsible for deployment are detailed in FIGS. 19A-19B. When performed in the reverse order, these actions also necessitate the first loading of a valve (not shown) prior to surgery.

As seen in FIG. 19A, manipulation of the thumbwheel 1616 will provide translational control of the sheath catheter 1604. In order to effect the deployment of a heart valve (not shown), the user must withdraw the sheath catheter 1604 from contact with the shoulder 1618 of the tip 1603 until it passes the larger diameter section 1623 of the bell catheter 1624. A heart valve (not shown) will reside concentrically above the guide-wire catheter 1621 in the position indicated by the leader for 1621 in FIG. 19A, similarly as to the embodiment illustrated in FIG. 13. The sheath catheter 1604 can be withdrawn until the screw insert 1627 comes into contact with the pin lock 1608. The pin lock 1608 must then be removed before further travel of the screw insert 1627 can be achieved.

As seen in FIG. 19B, the pin lock 1608 is removed from the handle 1601 in order to allow further translation of the sheath catheter 1604. When the sheath catheter 1604 is fully a ted, the larger diameter section 1623 of the bell catheter 1624 is also fully retracted, which completely frees the heart valve (not shown) from the delivery system. Three hub slots 1619, spaced circumferentially at 120° from each other provide the anchoring mechanism and physical link between delivery system and heart valve. Once the larger diameter section 1623 of the bell catheter 1624 has been withdrawn, the hub slots 1619 become uncovered which allows the heart valve anchor (not shown) to fully expand.

FIG. 20 illustrates a distal portion of the delivery device in FIG. 16. Three hub slots 1619 are slidably disposed distally relative to the large diameter tip 1623 of bell catheter 1624. These slots allow engagement with a prosthetic valve. The valve may be releasably held by the slots by disposing the commissure tabs or tabs 812 of the prosthetic valve into slots 1619 and then retracting the slots 1619 under tip 1623 of bell catheter 1624. The prosthetic valve may be released from the delivery catheter by advancing the slots distally relative to the bell catheter so that the loading anchors or tabs 812 may self-expand out of and away from slots 1619 when the constraint of tip 1623 on bell catheter 1624 has been removed.

FIG. 21 illustrates a prosthetic mitral valve 800 (as discussed above with reference to FIG. 8A) with the anchor tabs 812 disposed in the hub slots (not visible), and bell catheter 1623 advanced thereover. Thus, even though most of the prosthetic valve 800 has self-expanded into its expanded configuration, the valve commissures remain in a collapsed configuration with the tabs 812 captured in slots 1619. Once the constraint provided by bell catheter 1623 has been removed from the slots 1619, the tabs 812 may self-expand out of slots 1619, the commissures will open up to their unbiased position. The prosthetic valve is then disconnected and free from the delivery device.

Transapical Delivery Methods. FIGS. 22A-220 illustrate an exemplary method of transapically delivering a prosthetic mitral valve. This embodiment may use any of the prosthetic valves described herein, and may use any of the delivery devices described herein. FIG. 22A illustrates the general transapical pathway that is taken with entry into the heart at the apex 2202, through the left ventricle 2204, across the mitral valve 2206 and into the left atrium 2208. The aortic valve 2210 remains unaffected. Transapical delivery methods have been described in the patent and scientific literature, such as in International PCT Publication No. WO2009/134701, the entire contents of which are incorporated herein by reference.

In FIG. 22B a delivery device 2214 is introduced through an incision in the apex 2202 and over a guidewire GW through the ventricle 2204, past the mitral valve 2206 with a distal portion of the delivery device 2214 disposed in the atrium 2208. The delivery device has a rounded tip 2212 that is configured to pass through and dilate the incision, and can be advanced through the heart without causing unwanted trauma to the mitral valve 2206 or adjacent tissue. Suture 2216 may be stitched around the delivery device 2214 at the apex 2202 using a purse string stitch or other patterns known in the art in order to prevent excessive bleeding and to help hold the delivery device in position.

In FIG. 22C, the outer sheath 2214a of the delivery device 2214 is retracted proximally relative to the prosthetic mitral valve 2220 (or the prosthetic mitral valve is advanced distally relative to the outer sheath 2214a) to expose the alignment element 2218 and a portion of the atrial skirt region 2222 on the prosthetic mitral valve 2220 which allows the atrial skirt region 2222 to begin to partially radially expand outward and flare open. Alignment element 2218 may include a pair of radiopaque markers 2218a which facilitate visualization under fluoroscopy. The physician can then align the alignment element so that the radiopaque markers 2218a are disposed on either side of the anterior mitral valve leaflet. Delivery device 2214 may be rotated in order to help align the alignment element. The alignment element is preferably situated adjacent the aortic root and between the fibrous trigones of the native anterior leaflet.

In FIG. 22D once alignment has been obtained, the sheath 2214a is further retracted proximally, allowing radial expansion of the atrial skirt 2222 which flares outward to form a flange. Proximal retraction of the delivery device 2214 and prosthetic valve 2220 seat the atrial skirt 2222 against an atrial surface adjacent the mitral valve 2206 thereby anchoring the prosthetic valve in a first position.

FIG. 22E shows that further proximal retraction of sheath 2214a exposes and axially removes additional constraint from the prosthetic valve 2220, thereby allowing more of the valve to self-expand. The annular region 2224 expands into engagement with the mitral valve annulus and the ventricular trigonal tabs 2226 and the posterior tab 2228 radially expand. Portions of the ventricular skirt serve as deployment control regions and prevent the entire ventricular skirt from expanding because they are still constrained. The tabs are captured between the anterior and posterior mitral valve leaflets and the ventricular wall. The posterior ventricular anchoring tab 2228 is preferably aligned in the middle of the posterior mitral valve leaflet where there is an absence of chordae attachments, and is passed over the posterior leaflet to seat between the posterior leaflet and the ventricular wall. The two ventricular trigonal anchoring tabs 2226 are positioned on either side of the anterior leaflet with their heads positioned at the fibrous trigones. Slight rotation and realignment of the prosthesis can occur at this time. As the prosthesis expands, the anterior trigonal tabs anchor against the fibrous trigones, capturing the native anterior leaflet and chordae between the tabs and the anterior surface of the prosthetic valve, and the posterior ventricular tab anchors between the ventricular wall and the posterior leaflet, capturing the posterior leaflet between the posterior anchoring tab and the posterior surface of the prosthetic valve assembly.

FIG. 22F shows that further retraction of sheath 2214a releases the ventricular trigonal tabs and the posterior tab and the deployment control regions of the ventricular skirt 2230 are also released and allowed to radially expand outward against the native mitral valve leaflets. This creates a sealing funnel within the native leaflets and helps direct blood flow through the prosthetic mitral valve. With the commissures of the prosthesis still captured within the delivery system, very minor adjustments may still be made to ensure accurate positioning, anchoring and sealing. The prosthetic valve is now anchored in four positions. The anchor tabs 2232 are then released from the delivery device by retraction of an inner shaft, allowing the tabs to self-expand out of slots on the delivery catheter as previously discussed above and shown in FIG. 22G. The prosthetic valve is now implanted in the patient's heart and takes over the native mitral valve. The delivery device 2214 may then be removed from the heart by proximally retracting it and removing it from the apex incision. The suture 2216 may then be tied off, sealing the puncture site.

Transseptal Delivery Methods. FIGS. 23A-23G illustrate an exemplary method of transseptally delivering a prosthetic mitral valve. This embodiment may use any of the prosthetic valves described herein, and may use any of the delivery devices described herein if modified appropriately. One of skill in the art will appreciate that relative motion of the various shafts in the delivery system embodiments disclosed above may need to be reversed in order to accommodate a transseptal approach. FIG. 23A illustrates the general transseptal pathway that is taken with the delivery device passing up the vena cava 2302 into the right atrium 2304. A transseptal puncture 2306 is created through the atrial septum, often through the foramen ovale, so that the device may be passed into the left atrium 2308, above the mitral valve 2310 and adjacent the left ventricle 2312. Transseptal techniques have been published in the patent and scientific literature, such as in U.S. Patent Publication No. 2004/0181238 to Zarbatany et al., the entire contents of which are incorporated herein by reference.

In FIG. 23B a delivery device 2314 is passed over a guidewire GW through the vena cava 2302 into the right atrium 2306. The delivery device 23114 is then transseptally passed through the atrial wall into the left atrium 2308 adjacent the mitral valve 2310. The guidewire GW may be disposed across the mitral valve 2310 in the left ventricle 2312. The distal tip of the delivery device typically includes a nose cone or other atraumatic tip to prevent damaging the mitral valve or adjacent tissue.

In FIG. 23C, the outer sheath 2214a of the delivery device 2214 is retracted proximally relative to the prosthetic mitral valve 2319. Alternatively, a distal portion 2314b of the delivery device 2214 may be advanced distally relative to the prosthetic valve 2319 to expose the alignment element 2316 and a portion of the atrial skirt region 2318 on the prosthetic mitral valve 2319 which allows the atrial skirt region 2318 to begin to partially radially expand outward and flare open. Alignment element 23116 may include a pair of radiopaque markers 2316a which facilitate visualization under fluoroscopy. The physician can then align the alignment element so that the radiopaque markers 2316a are disposed on either side of the anterior mitral valve leaflet. The alignment element is preferably situated adjacent the aortic root and between the fibrous trigones of the native anterior leaflet. Delivery device 2214 may be rotated in order to help align the alignment element.

In FIG. 23D once alignment has been obtained, the distal portion 2314b is further advanced distally allowing radial expansion of the atrial skirt 2318 which flares outward to form a flange. Distally advancing the delivery device 2214 and prosthetic valve 2319 seats the atrial skirt 2318 against an atrial surface adjacent the mitral valve 2310 thereby anchoring the prosthetic valve in a first position.

FIG. 23E shows that further distal advancement of distal portion 2314b exposes and axially removes additional constraint from the prosthetic valve 2319, thereby allowing more of the valve to self-expand. The annular region 2320 expands into engagement with the mitral valve annulus and the ventricular trigonal tabs 2324 and the posterior tab 2322 radially expand. Portions of the ventricular skirt serve as deployment control regions since they remain constrained and thus the entire ventricular skirt cannot expand. The tabs are captured between the anterior and posterior mitral valve leaflets and the ventricular wall. The posterior ventricular anchoring tab 2322 is preferably aligned in the middle of the posterior mitral valve leaflet where there is an absence of chordae attachments, and is passed over the posterior leaflet to seat between the posterior leaflet and the ventricular wall. The two ventricular trigonal anchoring tabs 2324 are positioned on either side of the anterior leaflet with their heads positioned at the fibrous trigones. Slight rotation and realignment of the prosthesis can occur at this time. As the prosthesis expands, the anterior trigonal tabs anchor against the fibrous trigones, capturing the native anterior leaflet and chordae between the tabs and the anterior surface of the prosthetic valve, and the posterior ventricular tab anchors between the ventricular wall and the posterior leaflet, capturing the posterior leaflet between the posterior anchoring tab and the posterior surface of the prosthetic valve assembly.

FIG. 23F shows that further distal advancement of distal portion 2314b releases the ventricular trigonal tabs and the posterior tab and the ventricular skirt 2326 is also released and allowed to radially expand outward against the native mitral valve leaflets without engaging the ventricular wall. This creates a sealing funnel within the native leaflets and helps funnel blood flow through the prosthetic valve. With the commissures of the prosthetic valve still captured by the delivery system, very minor adjustments may still be made to ensure accurate positioning, anchoring and sealing. The prosthetic valve is now anchored in four positions. The anchor tabs 2328 are then released from the delivery device by further advancement of an inner shaft, allowing the tabs to self-expand out of slots on the delivery catheter as previously discussed above and shown in FIG. 23G. The prosthetic valve is now implanted in the patient's heart and takes over the native mitral valve. The delivery device 2314 may then be removed from the heart by proximally retracting it back through the atrial septum, and out of the vena cava.

FIG. 24 shows the prosthetic valve 2418 anchored in the mitral space after transapical or transseptal delivery. Prosthetic valve 2418 is preferably the prosthetic mitral valve illustrated in FIG. 8A, and delivered by methods shown in FIGS. 22A-22G or FIGS. 23A-23G. The prosthetic valve 2418 has radially self-expanded into engagement with the mitral valve to anchor it in position without obstructing other portions of the heart including the left ventricular outflow tract such as aortic valve 2402. The anterior trigonal tabs 2408 (only 1 seen in this view) and the posterior ventricular tab 2405 are radially expanded outward from the rest of the ventricular skirt 2410 and the anterior leaflet 2406 and posterior leaflet 2404 are captured between the respective tab and the ventricular skirt 2410 to form an anchor point. The ventricular skirt 2410 is also radially expanded outward to engage and press outwardly at least some of the chordae tendineae and papillary muscles but preferably without pressing against the ventricular wall. The annular region 2416 is expanded radially outward to engage and press against the mitral valve annulus, and the atrial skirt 2414 has also expanded outwardly to form a flange that rests on top of the mitral valve against the atrium. Thus, the prosthetic valve 2418 is anchored in four positions in the mitral space which prevents the prosthetic valve from migrating or dislodging during contraction of the heart. Moreover, using four anchor points lessens the anchoring pressure that is required to be applied in any given anchoring zone as compared to a prosthesis that is anchored in only a single anchoring zone, or in any combination of these four anchoring zones. The consequent reduction in radial force required to be exerted against the native structures in each zone minimizes the risk of obstruction or impingement of the nearby aortic valve or aortic root caused by the displacement of the native mitral valve apparatus. Valve leaflets 2420 form a tricuspid valve which opens with antegrade blood flow and closes with retrograde blood flow. Tab 2412 on a tip of the commissures 2421 (best seen in FIG. 25) remains free after disengagement from the delivery device.

FIG. 25 illustrates the prosthetic valve 2418 of FIG. 24 anchored in the mitral space and viewed from the left ventricle, looking upward toward the atrium. As previously mentioned, the prosthetic valve 2418 may be transapically or transseptally delivered and is preferably the prosthetic mitral valve illustrated in FIG. 8A, delivered by methods shown in FIGS. 22A-22G or FIGS. 23A-23G. This view more clearly illustrates anchoring and engagement of the prosthetic mitral valve 2418 with the adjacent tissue. For example, the three valve leaflets 2420 forming the tricuspid valve are shown in the open position, allowing blood flow therepast. Additionally, the anterior trigonal tabs 2408 and the posterior ventricular tab 2405 are shown radially expanded outward into engagement with the ventricular heart tissue 2425. The anterior portion of the prosthetic valve in between anterior trigonal tabs 2408 is approximately flat to match the corresponding flat anatomy as previously discussed above. The flat shape of the anterior portion of the prosthetic valve prevents the prosthetic valve from impinging on and obstructing adjacent anatomy such as the left ventricular outflow tract including the aortic valve. FIG. 25 also illustrates how the ventricular skirt 2410 expands radially outward against the native mitral valve leaflets.

Drug Delivery. Any of the prosthetic valves may also be used as a drug delivery device for localized drug elution. The therapeutic agent may be a coated on the prosthetic valve, on the tissue covering the anchor, on both, or otherwise carried by the prosthetic valve and controllably eluted therefrom after implantation. Exemplary drugs include anti-calcification drugs, antibiotics, anti-platelet aggregation drugs, anti-inflammatory drugs, drugs which inhibit tissue rejection, anti-restenosis drugs, anti-thrombogenic drugs, thrombolytic drugs, etc. Drugs which have these therapeutic effects are well known to those of skill in the art.

Although the exemplary embodiments have been described in some detail for clarity of understanding and by way of example, a variety of additional modifications, adaptations and changes may be clear to those of skill in the art. One of skill in the art will appreciate that the various features described herein may be combined with one another or substituted with one another. Hence, the scope of the present invention is limited solely by the appended claims.

Claims

1. A system for treating mitral regurgitation, comprising: a mitral valve prosthesis comprising: an expandable frame having a collapsed configuration for delivery and an expanded configuration for anchoring within a native mitral valve, the expandable frame comprising: an atrial region configured to be positioned within a left atrium of a patient, wherein the atrial region comprises a plurality of triangular fingers that extend radially outwardly when the expandable frame is in the expanded configuration to form a flat surface configured to cover an atrial surface adjacent the native mitral valve;an annular region configured to be positioned within a native mitral valve annulus of the native mitral valve;a ventricular region configured to be positioned downstream of the annular region, wherein the ventricular region has a larger cross-sectional dimension than a cross-sectional dimension of the annular region when the expandable frame is in the expanded configuration; anda plurality of ventricular anchors extending from the ventricular region in an upstream direction toward the atrial region when the expandable frame is in the expanded configuration, at least some of the plurality of ventricular anchors being sized and configured to extend behind a native leaflet of the native mitral valve to capture the native leaflet between the ventricular anchors and the ventricular region of the expandable frame; anda plurality of prosthetic valve leaflets positioned within the expandable frame configured to allow antegrade blood flow in a downstream direction from the atrial region toward the ventricular region and prevent retrograde blood flow in an upstream direction from the ventricular region toward the atrial region; anda delivery device for delivering the mitral valve prosthesis to the native mitral valve, the delivery device comprising: an outer catheter having a proximal section and a distal section configured to contain at least a portion the mitral valve prosthesis therein with the expandable frame in the collapsed configuration; andan inner catheter extending within the outer catheter and configured to releasably engage anchoring tabs on the expandable frame;wherein the delivery device is controllable to slide the outer catheter relative to the inner catheter to cause at least a portion of the expandable frame to at least partially expand to the expanded configuration.
2. The system of claim 1, wherein the delivery device is configured to deliver the mitral valve prosthesis transseptally.
3. The system of claim 1, wherein the mitral valve prosthesis is configured to self-expand when released from the delivery device.
4. The system of claim 1, wherein at least some of the plurality of ventricular anchors are sized and configured to capture chordae and the native leaflet between the ventricular anchors and the ventricular region of the expandable frame.
5. The system of claim 1, wherein the ventricular anchors have rounded tips.
6. The system of claim 1, wherein the anchoring tabs are mushroom shaped.
7. The system of claim 1, wherein the inner catheter comprises a hub for releasably engaging the anchoring tabs on the expandable frame.
8. The system of claim 7, wherein the distal section of the outer catheter has a diameter larger than a diameter of the proximal section, and wherein the distal section is configured to cover the hub when the outer catheter is advanced distally relative to the hub, and is configured to uncover the hub when the outer catheter is retracted proximally relative to the hub to thereby release the inner catheter from the anchoring tabs.
9. The system of claim 1, wherein the delivery device further comprises a sheath slidably and concentrically disposed over the outer catheter, wherein the sheath is configured to be disposed over the distal section of the outer catheter during delivery of the mitral valve prosthesis.

CROSS-REFERENCES TO RELATED APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 15/682,890, filed Aug. 22, 2017, which is a continuation of U.S. patent application Ser. No. 14/046,606, filed Oct. 4, 2013, now U.S. Pat. No. 9,770,329, which is a divisional of U.S. patent application Ser. No. 13/096,572, filed Apr. 28, 2011, now U.S. Pat. No. 8,579,964, which claims the benefit of U.S. Provisional Patent Applications Nos. 61/414,879, filed Nov. 17, 2010; 61/393,860, filed Oct. 15, 2010; and 61/331,799, filed May 5, 2010; the entire contents of each of which are incorporated herein by reference.

US Referenced Citations (931)

Number	Name	Date	Kind
3657744	Ersek	Apr 1972	A
3671979	Moulopoulos	Jun 1972	A
3739402	Cooley et al.	Jun 1973	A
4056854	Boretos et al.	Nov 1977	A
4079468	Liotta et al.	Mar 1978	A
4204283	Bellhouse et al.	May 1980	A
4222126	Boretos et al.	Sep 1980	A
4265694	Boretos et al.	May 1981	A
4339831	Johnson	Jul 1982	A
4340977	Brownlee et al.	Jul 1982	A
4470157	Love	Sep 1984	A
4477930	Totten et al.	Oct 1984	A
4490859	Black et al.	Jan 1985	A
4553545	Maass et al.	Nov 1985	A
4655771	Wallsten	Apr 1987	A
4733665	Palmaz	Mar 1988	A
4776337	Palmaz	Oct 1988	A
4777951	Cribier et al.	Oct 1988	A
4865600	Carpentier et al.	Sep 1989	A
4950227	Savin et al.	Aug 1990	A
4994077	Dobben	Feb 1991	A
5067957	Jervis	Nov 1991	A
5197978	Hess	Mar 1993	A
5326371	Love et al.	Jul 1994	A
5332402	Teitelbaum	Jul 1994	A
5344427	Cottenceau et al.	Sep 1994	A
5370685	Stevens	Dec 1994	A
5397355	Marin et al.	Mar 1995	A
5411552	Andersen et al.	May 1995	A
5415667	Frater	May 1995	A
5439446	Barry	Aug 1995	A
5474563	Myler et al.	Dec 1995	A
5509930	Love	Apr 1996	A
5545214	Stevens	Aug 1996	A
5554185	Block et al.	Sep 1996	A
5575818	Pinchuk	Nov 1996	A
5607444	Lam	Mar 1997	A
5607469	Frey	Mar 1997	A
5669919	Sanders et al.	Sep 1997	A
5697382	Love et al.	Dec 1997	A
D390957	Fontaine	Feb 1998	S
5713952	Vanney et al.	Feb 1998	A
5725519	Penner et al.	Mar 1998	A
5769812	Stevens et al.	Jun 1998	A
5807398	Shaknovich	Sep 1998	A
5810873	Morales	Sep 1998	A
5840081	Andersen et al.	Nov 1998	A
5855601	Bessler et al.	Jan 1999	A
5868777	Lam	Feb 1999	A
5868782	Frantzen	Feb 1999	A
5876437	Vanney et al.	Mar 1999	A
5879381	Moriuchi et al.	Mar 1999	A
5902334	Dwyer et al.	May 1999	A
5928281	Huynh et al.	Jul 1999	A
5935108	Katoh et al.	Aug 1999	A
5954764	Parodi	Sep 1999	A
5957949	Leonhardt et al.	Sep 1999	A
5992000	Humphrey et al.	Nov 1999	A
6004328	Solar	Dec 1999	A
6015431	Thornton et al.	Jan 2000	A
6042606	Frantzen	Mar 2000	A
6053940	Wijay	Apr 2000	A
6074417	Peredo	Jun 2000	A
6086612	Jansen	Jul 2000	A
6113612	Swanson et al.	Sep 2000	A
6113631	Jansen	Sep 2000	A
6132458	Staehle et al.	Oct 2000	A
6152937	Peterson et al.	Nov 2000	A
6159237	Alt et al.	Dec 2000	A
6168614	Andersen et al.	Jan 2001	B1
6168616	Brown, III	Jan 2001	B1
6251093	Valley et al.	Jun 2001	B1
6280466	Kugler et al.	Aug 2001	B1
6306141	Jervis	Oct 2001	B1
6312465	Griffin et al.	Nov 2001	B1
6336938	Kavteladze et al.	Jan 2002	B1
6352543	Cole	Mar 2002	B1
6358277	Duran	Mar 2002	B1
6425916	Garrison et al.	Jul 2002	B1
6440164	DiMatteo et al.	Aug 2002	B1
6458153	Bailey et al.	Oct 2002	B1
6475237	Drasler et al.	Nov 2002	B2
6482228	Norred	Nov 2002	B1
6511491	Grudem et al.	Jan 2003	B2
6517573	Pollock et al.	Feb 2003	B1
6527800	McGuckin, Jr. et al.	Mar 2003	B1
6551303	Van Tassel et al.	Apr 2003	B1
6582462	Andersen et al.	Jun 2003	B1
6602281	Klein	Aug 2003	B1
6610088	Gabbay	Aug 2003	B1
6641606	Ouriel et al.	Nov 2003	B2
6652578	Bailey et al.	Nov 2003	B2
D484979	Fontaine	Jan 2004	S
6676698	McGuckin, Jr. et al.	Jan 2004	B2
6682537	Ouriel et al.	Jan 2004	B2
6695878	McGuckin, Jr. et al.	Feb 2004	B2
6702843	Brown et al.	Mar 2004	B1
6712836	Berg et al.	Mar 2004	B1
6723123	Kazatchkov et al.	Apr 2004	B1
6730118	Spenser et al.	May 2004	B2
6733523	Shaolian et al.	May 2004	B2
6764505	Hossainy et al.	Jul 2004	B1
6767362	Schreck	Jul 2004	B2
6780200	Jansen	Aug 2004	B2
6790229	Berreklouw	Sep 2004	B1
6790230	Beyersdorf et al.	Sep 2004	B2
6814746	Thompson et al.	Nov 2004	B2
6858034	Hijlkema et al.	Feb 2005	B1
6875231	Anduiza et al.	Apr 2005	B2
6893460	Spenser et al.	May 2005	B2
6908477	McGuckin, Jr. et al.	Jun 2005	B2
6908481	Cribier	Jun 2005	B2
6926732	Derus et al.	Aug 2005	B2
6929660	Ainsworth et al.	Aug 2005	B1
6936058	Forde et al.	Aug 2005	B2
6979350	Moll et al.	Dec 2005	B2
7018401	Hyodoh et al.	Mar 2006	B1
7018406	Seguin et al.	Mar 2006	B2
7025780	Gabbay	Apr 2006	B2
7044962	Elliott	May 2006	B2
7044966	Svanidze et al.	May 2006	B2
7087088	Berg et al.	Aug 2006	B2
7147660	Chobotov et al.	Dec 2006	B2
7147661	Chobotov et al.	Dec 2006	B2
7147663	Berg et al.	Dec 2006	B1
7153322	Alt	Dec 2006	B2
7186265	Sharkawy et al.	Mar 2007	B2
7198646	Figulla et al.	Apr 2007	B2
7201772	Schwammenthal et al.	Apr 2007	B2
7252682	Seguin	Aug 2007	B2
D553747	Fliedner	Oct 2007	S
7276078	Spenser et al.	Oct 2007	B2
7276084	Yang et al.	Oct 2007	B2
7329278	Seguin et al.	Feb 2008	B2
7338520	Bailey et al.	Mar 2008	B2
7381219	Salahieh et al.	Jun 2008	B2
7393360	Spenser et al.	Jul 2008	B2
7429269	Schwammenthal et al.	Sep 2008	B2
7435257	Lashinski et al.	Oct 2008	B2
7442204	Schwammenthal et al.	Oct 2008	B2
7445631	Salahieh et al.	Nov 2008	B2
7455689	Johnson	Nov 2008	B2
7462191	Spenser et al.	Dec 2008	B2
7510575	Spenser et al.	Mar 2009	B2
7524330	Berreklouw	Apr 2009	B2
7527646	Rahdert et al.	May 2009	B2
7585321	Cribier	Sep 2009	B2
7608114	Levine et al.	Oct 2009	B2
7615072	Rust et al.	Nov 2009	B2
7618446	Andersen et al.	Nov 2009	B2
7618447	Case et al.	Nov 2009	B2
7628805	Spenser et al.	Dec 2009	B2
7632298	Hijlkema et al.	Dec 2009	B2
7637945	Solem et al.	Dec 2009	B2
7637946	Solem et al.	Dec 2009	B2
7682390	Seguin	Mar 2010	B2
7708775	Rowe et al.	May 2010	B2
7712606	Salahieh et al.	May 2010	B2
7748389	Salahieh et al.	Jul 2010	B2
7753949	Lamphere et al.	Jul 2010	B2
D622387	Igaki	Aug 2010	S
D622388	Igaki	Aug 2010	S
7771463	Ton et al.	Aug 2010	B2
7771472	Hendricksen et al.	Aug 2010	B2
7780725	Haug et al.	Aug 2010	B2
7785360	Freitag	Aug 2010	B2
7799072	Greenberg	Sep 2010	B2
7803185	Gabbay	Sep 2010	B2
7806917	Xiao	Oct 2010	B2
7806919	Bloom et al.	Oct 2010	B2
7815589	Meade et al.	Oct 2010	B2
7815673	Bloom et al.	Oct 2010	B2
7824443	Salahieh et al.	Nov 2010	B2
7837727	Goetz et al.	Nov 2010	B2
7846203	Cribier	Dec 2010	B2
7871435	Carpentier et al.	Jan 2011	B2
7892281	Seguin et al.	Feb 2011	B2
D635261	Rossi	Mar 2011	S
D635262	Rossi	Mar 2011	S
7896915	Guyenot et al.	Mar 2011	B2
7914569	Nguyen et al.	Mar 2011	B2
7914575	Guyenot et al.	Mar 2011	B2
7919112	Pathak et al.	Apr 2011	B2
7947075	Goetz et al.	May 2011	B2
7959672	Salahieh et al.	Jun 2011	B2
7967853	Eidenschink et al.	Jun 2011	B2
7972377	Lane	Jul 2011	B2
7972378	Tabor et al.	Jul 2011	B2
7981151	Rowe	Jul 2011	B2
7993392	Righini et al.	Aug 2011	B2
7993394	Hariton et al.	Aug 2011	B2
7993395	Vanermen et al.	Aug 2011	B2
7998196	Mathison	Aug 2011	B2
8009887	Ionasec et al.	Aug 2011	B2
8016870	Chew et al.	Sep 2011	B2
8016877	Seguin et al.	Sep 2011	B2
8029564	Johnson et al.	Oct 2011	B2
8048153	Salahieh et al.	Nov 2011	B2
8052747	Melnikov et al.	Nov 2011	B2
8052750	Tuval et al.	Nov 2011	B2
8057538	Bergin et al.	Nov 2011	B2
8057539	Ghione et al.	Nov 2011	B2
8057540	Letac et al.	Nov 2011	B2
8062350	Gale et al.	Nov 2011	B2
8062359	Marquez et al.	Nov 2011	B2
8066763	Alt	Nov 2011	B2
8070799	Righini et al.	Dec 2011	B2
8070800	Lock et al.	Dec 2011	B2
8070801	Cohn	Dec 2011	B2
8070802	Lamphere et al.	Dec 2011	B2
8075615	Eberhardt et al.	Dec 2011	B2
8078279	Dennis et al.	Dec 2011	B2
8080054	Rowe	Dec 2011	B2
8083793	Lane et al.	Dec 2011	B2
8088158	Brodeur	Jan 2012	B2
8088404	Udipi et al.	Jan 2012	B2
8092520	Quadri	Jan 2012	B2
8100964	Spence	Jan 2012	B2
8105375	Navia et al.	Jan 2012	B2
8105377	Liddicoat	Jan 2012	B2
8109995	Paniagua et al.	Feb 2012	B2
8109996	Stacchino et al.	Feb 2012	B2
8114154	Righini et al.	Feb 2012	B2
8118866	Herrmann et al.	Feb 2012	B2
8119704	Wang et al.	Feb 2012	B2
8123801	Milo	Feb 2012	B2
8128681	Shoemaker et al.	Mar 2012	B2
8128688	Ding et al.	Mar 2012	B2
8136218	Millwee et al.	Mar 2012	B2
8137398	Tuval et al.	Mar 2012	B2
8137687	Chen et al.	Mar 2012	B2
8142492	Forster et al.	Mar 2012	B2
8142494	Rahdert et al.	Mar 2012	B2
8147504	Ino et al.	Apr 2012	B2
8155754	Nygren et al.	Apr 2012	B2
8157852	Bloom et al.	Apr 2012	B2
8157853	Laske et al.	Apr 2012	B2
8158187	Chen et al.	Apr 2012	B2
8163014	Lane et al.	Apr 2012	B2
8167926	Hartley et al.	May 2012	B2
8167932	Bourang et al.	May 2012	B2
8167934	Styrc et al.	May 2012	B2
8168275	Lee et al.	May 2012	B2
8177799	Orban, III	May 2012	B2
8177836	Lee et al.	May 2012	B2
8180428	Kaiser et al.	May 2012	B2
8182528	Salahieh et al.	May 2012	B2
8182530	Huber	May 2012	B2
8182829	Kleiner et al.	May 2012	B2
8187851	Shah et al.	May 2012	B2
8195293	Limousin et al.	Jun 2012	B2
8202529	Hossainy et al.	Jun 2012	B2
8211169	Lane et al.	Jul 2012	B2
8216261	Solem	Jul 2012	B2
8216301	Bonhoeffer et al.	Jul 2012	B2
8219229	Cao et al.	Jul 2012	B2
8220121	Hendriksen et al.	Jul 2012	B2
8221482	Cottone et al.	Jul 2012	B2
8221493	Boyle et al.	Jul 2012	B2
8226710	Nguyen et al.	Jul 2012	B2
8231930	Castro et al.	Jul 2012	B2
D665079	Zago	Aug 2012	S
D665080	Zago	Aug 2012	S
8236045	Benichou et al.	Aug 2012	B2
8236241	Carpentier et al.	Aug 2012	B2
8241274	Keogh et al.	Aug 2012	B2
8246675	Zegdi	Aug 2012	B2
8246677	Ryan	Aug 2012	B2
8246678	Salahieh et al.	Aug 2012	B2
8252051	Chau et al.	Aug 2012	B2
8252052	Salahieh et al.	Aug 2012	B2
8257724	Cromack et al.	Sep 2012	B2
8257725	Cromack et al.	Sep 2012	B2
8262724	Seguin et al.	Sep 2012	B2
8273118	Bergin	Sep 2012	B2
8273120	Dolan	Sep 2012	B2
8276533	Chambers et al.	Oct 2012	B2
8287584	Salahieh et al.	Oct 2012	B2
8287591	Keidar et al.	Oct 2012	B2
8303653	Bonhoeffer et al.	Nov 2012	B2
8308798	Pintor et al.	Nov 2012	B2
8313520	Barbut et al.	Nov 2012	B2
8313525	Tuval et al.	Nov 2012	B2
8317854	Ryan et al.	Nov 2012	B1
8323335	Rowe et al.	Dec 2012	B2
8323336	Hill et al.	Dec 2012	B2
8337541	Quadri et al.	Dec 2012	B2
8348995	Tuval et al.	Jan 2013	B2
8349001	Mensah et al.	Jan 2013	B2
8349003	Shu et al.	Jan 2013	B2
8353921	Schaller et al.	Jan 2013	B2
8353948	Besselink et al.	Jan 2013	B2
8353953	Giannetti et al.	Jan 2013	B2
8357387	Dove et al.	Jan 2013	B2
8361137	Perouse	Jan 2013	B2
8361537	Shanley	Jan 2013	B2
8366769	Huynh et al.	Feb 2013	B2
8377116	Hsu et al.	Feb 2013	B2
8377499	Kleiner et al.	Feb 2013	B2
8382816	Pollock et al.	Feb 2013	B2
RE44075	Williamson et al.	Mar 2013	E
8398707	Bergin	Mar 2013	B2
8398708	Meiri et al.	Mar 2013	B2
8403983	Quadri et al.	Mar 2013	B2
8408214	Spenser	Apr 2013	B2
8409274	Li et al.	Apr 2013	B2
8414635	Hyodoh et al.	Apr 2013	B2
8414643	Tuval et al.	Apr 2013	B2
8414644	Quadri et al.	Apr 2013	B2
8414645	Dwork et al.	Apr 2013	B2
8430902	Bergheim	Apr 2013	B2
8444689	Zhang	May 2013	B2
8449466	Duhay et al.	May 2013	B2
8449599	Chau et al.	May 2013	B2
8449625	Campbell et al.	May 2013	B2
8454684	Bergin et al.	Jun 2013	B2
8454685	Hariton et al.	Jun 2013	B2
8460335	Carpenter	Jun 2013	B2
8460365	Haverkost et al.	Jun 2013	B2
8460366	Rowe	Jun 2013	B2
8460370	Zakay et al.	Jun 2013	B2
8460373	Fogarty et al.	Jun 2013	B2
8470023	Eidenschink et al.	Jun 2013	B2
8470024	Ghione et al.	Jun 2013	B2
8475521	Suri et al.	Jul 2013	B2
8475522	Jimenez et al.	Jul 2013	B2
8475523	Duffy	Jul 2013	B2
8479380	Malewicz et al.	Jul 2013	B2
8480730	Maurer et al.	Jul 2013	B2
8480731	Elizondo et al.	Jul 2013	B2
8486137	Suri et al.	Jul 2013	B2
8491650	Wiemeyer et al.	Jul 2013	B2
8500688	Engel et al.	Aug 2013	B2
8500755	Ino et al.	Aug 2013	B2
8500798	Rowe et al.	Aug 2013	B2
8500801	Eberhardt et al.	Aug 2013	B2
8500802	Lane et al.	Aug 2013	B2
8506620	Ryan	Aug 2013	B2
8506625	Johnson	Aug 2013	B2
8511244	Holecek et al.	Aug 2013	B2
8512397	Rolando et al.	Aug 2013	B2
8512398	Alkhatib	Aug 2013	B2
8512399	Lafontaine	Aug 2013	B2
8512401	Murray, III et al.	Aug 2013	B2
8518106	Duffy et al.	Aug 2013	B2
8518108	Huynh et al.	Aug 2013	B2
8529621	Alfieri et al.	Sep 2013	B2
8535368	Headley, Jr. et al.	Sep 2013	B2
8539662	Stacchino et al.	Sep 2013	B2
8545742	Gada et al.	Oct 2013	B2
8551162	Fogarty et al.	Oct 2013	B2
8562663	Mearns et al.	Oct 2013	B2
8562672	Bonhoeffer et al.	Oct 2013	B2
8562673	Yeung et al.	Oct 2013	B2
8565872	Pederson	Oct 2013	B2
8568472	Marchand et al.	Oct 2013	B2
8579964	Lane et al.	Nov 2013	B2
8579965	Bonhoeffer et al.	Nov 2013	B2
8584849	McCaffrey	Nov 2013	B2
8585749	Shelso	Nov 2013	B2
8585755	Chau et al.	Nov 2013	B2
8585756	Bonhoeffer et al.	Nov 2013	B2
8591570	Revuelta et al.	Nov 2013	B2
8591574	Lambrecht et al.	Nov 2013	B2
8597348	Rowe et al.	Dec 2013	B2
8603154	Strauss et al.	Dec 2013	B2
8603160	Salahieh et al.	Dec 2013	B2
8603161	Drews et al.	Dec 2013	B2
8608648	Banik et al.	Dec 2013	B2
8617236	Paul et al.	Dec 2013	B2
8623074	Ryan	Jan 2014	B2
8623080	Fogarty et al.	Jan 2014	B2
8628566	Eberhardt et al.	Jan 2014	B2
8632586	Spenser et al.	Jan 2014	B2
8632608	Carpentier et al.	Jan 2014	B2
8640521	Righini et al.	Feb 2014	B2
8641639	Manstrom et al.	Feb 2014	B2
8647381	Essinger et al.	Feb 2014	B2
8652201	Oberti et al.	Feb 2014	B2
8652202	Alon et al.	Feb 2014	B2
8652203	Quadri et al.	Feb 2014	B2
8653632	Pederson et al.	Feb 2014	B2
8663318	Ho	Mar 2014	B2
8663319	Ho	Mar 2014	B2
8668730	McGuckin, Jr. et al.	Mar 2014	B2
8668733	Haug et al.	Mar 2014	B2
8672992	Orr	Mar 2014	B2
8672997	Drasler et al.	Mar 2014	B2
8672998	Lichtenstein et al.	Mar 2014	B2
8672999	Cali et al.	Mar 2014	B2
8673000	Tabor et al.	Mar 2014	B2
8679174	Ottma et al.	Mar 2014	B2
8679404	Liburd et al.	Mar 2014	B2
8685083	Perier et al.	Apr 2014	B2
8685086	Navia et al.	Apr 2014	B2
8690787	Blomqvist et al.	Apr 2014	B2
8690936	Nguyen et al.	Apr 2014	B2
8696742	Pintor et al.	Apr 2014	B2
8707957	Callister et al.	Apr 2014	B2
8715207	Righini et al.	May 2014	B2
8715337	Chuter	May 2014	B2
8715343	Navia et al.	May 2014	B2
8721707	Boucher et al.	May 2014	B2
8721708	Seguin et al.	May 2014	B2
8721713	Tower et al.	May 2014	B2
8721714	Kelley	May 2014	B2
8728154	Alkhatib	May 2014	B2
8728155	Montorfano et al.	May 2014	B2
8731658	Hampton et al.	May 2014	B2
8734484	Ahlberg et al.	May 2014	B2
8740930	Goodwin	Jun 2014	B2
8740974	Lambrecht et al.	Jun 2014	B2
8740975	Yang et al.	Jun 2014	B2
8740976	Tran et al.	Jun 2014	B2
8747458	Tuval et al.	Jun 2014	B2
8747459	Nguyen et al.	Jun 2014	B2
8747460	Tuval et al.	Jun 2014	B2
8753384	Leanna	Jun 2014	B2
8758432	Solem	Jun 2014	B2
8764814	Solem	Jul 2014	B2
8764820	Dehdashtian et al.	Jul 2014	B2
8771302	Woolfson et al.	Jul 2014	B2
8771344	Tran et al.	Jul 2014	B2
8771345	Tuval et al.	Jul 2014	B2
8771346	Tuval et al.	Jul 2014	B2
8777975	Kashkarov et al.	Jul 2014	B2
8778018	Iobbi	Jul 2014	B2
8784478	Tuval et al.	Jul 2014	B2
8784480	Taylor et al.	Jul 2014	B2
8784481	Alkhatib et al.	Jul 2014	B2
8790387	Nguyen et al.	Jul 2014	B2
8790395	Straubinger et al.	Jul 2014	B2
8790396	Bergheim et al.	Jul 2014	B2
8791171	Pacetti	Jul 2014	B2
8795356	Quadri et al.	Aug 2014	B2
8801776	House	Aug 2014	B2
8808366	Braido et al.	Aug 2014	B2
8808370	Nitzan et al.	Aug 2014	B2
8821569	Gurskis et al.	Sep 2014	B2
8821570	DuMontelle et al.	Sep 2014	B2
8828078	Salahieh et al.	Sep 2014	B2
8828079	Thielen et al.	Sep 2014	B2
8834561	Figulla et al.	Sep 2014	B2
8834564	Tuval et al.	Sep 2014	B2
8840661	Manasse	Sep 2014	B2
8845718	Tuval et al.	Sep 2014	B2
8845720	Conklin	Sep 2014	B2
8852267	Cattaneo	Oct 2014	B2
8858620	Salahieh et al.	Oct 2014	B2
8858621	Oba et al.	Oct 2014	B2
8870936	Rowe	Oct 2014	B2
8870947	Shaw	Oct 2014	B2
8870948	Erzberger et al.	Oct 2014	B1
8876712	Yee et al.	Nov 2014	B2
8876883	Rust	Nov 2014	B2
8876893	Dwork et al.	Nov 2014	B2
8876894	Tuval et al.	Nov 2014	B2
8876895	Tuval et al.	Nov 2014	B2
8882831	Alkhatib	Nov 2014	B2
8894702	Quadri et al.	Nov 2014	B2
8894703	Salahieh et al.	Nov 2014	B2
8906081	Cully et al.	Dec 2014	B2
8911455	Quadri et al.	Dec 2014	B2
8911844	Ford	Dec 2014	B2
8926688	Burkart et al.	Jan 2015	B2
8926693	Duffy et al.	Jan 2015	B2
8932349	Jenson et al.	Jan 2015	B2
8940887	Chatterton et al.	Jan 2015	B2
8945208	Jimenez et al.	Feb 2015	B2
8945209	Bonyuet et al.	Feb 2015	B2
8945210	Cartledge et al.	Feb 2015	B2
8951280	Cohn et al.	Feb 2015	B2
8951299	Paul et al.	Feb 2015	B2
8961583	Hojeibane et al.	Feb 2015	B2
8961589	Kleiner et al.	Feb 2015	B2
8961593	Bonhoeffer et al.	Feb 2015	B2
8961595	Alkhatib	Feb 2015	B2
8968393	Rothstein	Mar 2015	B2
8968395	Hauser et al.	Mar 2015	B2
8974524	Yeung et al.	Mar 2015	B2
8979922	Jayasinghe et al.	Mar 2015	B2
8986372	Murry, III et al.	Mar 2015	B2
8986713	Cleek et al.	Mar 2015	B2
8992608	Haug et al.	Mar 2015	B2
8998978	Wang	Apr 2015	B2
8998979	Seguin et al.	Apr 2015	B2
8998980	Shipley et al.	Apr 2015	B2
8998981	Tuval et al.	Apr 2015	B2
8999369	Gale et al.	Apr 2015	B2
9005273	Salahieh et al.	Apr 2015	B2
9005277	Pintor et al.	Apr 2015	B2
9011521	Haug et al.	Apr 2015	B2
9011523	Seguin	Apr 2015	B2
9011524	Eberhardt	Apr 2015	B2
9011528	Ryan et al.	Apr 2015	B2
9023100	Quadri et al.	May 2015	B2
9028545	Taylor	May 2015	B2
9029418	Dove et al.	May 2015	B2
9034033	McLean et al.	May 2015	B2
9055937	Rowe et al.	Jun 2015	B2
9078749	Lutter et al.	Jul 2015	B2
9078751	Naor	Jul 2015	B2
9084676	Chau et al.	Jul 2015	B2
9125738	Figulla et al.	Sep 2015	B2
9138312	Tuval et al.	Sep 2015	B2
9161834	Taylor et al.	Oct 2015	B2
9241790	Lane et al.	Jan 2016	B2
9248014	Lane et al.	Feb 2016	B2
D755384	Pesce et al.	May 2016	S
9333074	Quadri et al.	May 2016	B2
20010007956	Letac et al.	Jul 2001	A1
20010021872	Bailey et al.	Sep 2001	A1
20010047180	Grudem et al.	Nov 2001	A1
20010047200	White et al.	Nov 2001	A1
20020016623	Kula et al.	Feb 2002	A1
20020022853	Swanson et al.	Feb 2002	A1
20020032481	Gabbay	Mar 2002	A1
20020045929	Diaz	Apr 2002	A1
20020052644	Shaolian et al.	May 2002	A1
20020055772	McGuckin et al.	May 2002	A1
20020111619	Keast et al.	Aug 2002	A1
20020183827	Derus et al.	Dec 2002	A1
20030040792	Gabbay	Feb 2003	A1
20030105517	White et al.	Jun 2003	A1
20030114913	Spenser et al.	Jun 2003	A1
20030120263	Ouriel et al.	Jun 2003	A1
20030120330	Ouriel et al.	Jun 2003	A1
20030120333	Ouriel et al.	Jun 2003	A1
20030125797	Chobotov et al.	Jul 2003	A1
20030130729	Paniagua et al.	Jul 2003	A1
20030176914	Rabkin et al.	Sep 2003	A1
20030199971	Tower et al.	Oct 2003	A1
20030220683	Minasian et al.	Nov 2003	A1
20040039436	Spenser et al.	Feb 2004	A1
20040087900	Thompson et al.	May 2004	A1
20040093058	Cottone et al.	May 2004	A1
20040093060	Seguin et al.	May 2004	A1
20040102842	Jansen	May 2004	A1
20040117009	Cali et al.	Jun 2004	A1
20040133273	Cox	Jul 2004	A1
20040181238	Zarbatany et al.	Sep 2004	A1
20040186561	McGuckin et al.	Sep 2004	A1
20040193261	Berreklouw	Sep 2004	A1
20040210304	Seguin et al.	Oct 2004	A1
20040210307	Khairkhahan	Oct 2004	A1
20040215325	Penn et al.	Oct 2004	A1
20040225353	McGuckin et al.	Nov 2004	A1
20040236411	Sarac et al.	Nov 2004	A1
20040243230	Navia et al.	Dec 2004	A1
20040249433	Freitag	Dec 2004	A1
20040260390	Sarac et al.	Dec 2004	A1
20050033398	Seguin	Feb 2005	A1
20050038470	van der Burg et al.	Feb 2005	A1
20050075727	Wheatley	Apr 2005	A1
20050090887	Pryor	Apr 2005	A1
20050096738	Cali et al.	May 2005	A1
20050107872	Mensah et al.	May 2005	A1
20050125020	Meade et al.	Jun 2005	A1
20050137682	Justino	Jun 2005	A1
20050137686	Salahieh et al.	Jun 2005	A1
20050137687	Salahieh et al.	Jun 2005	A1
20050137690	Salahieh et al.	Jun 2005	A1
20050137691	Salahieh et al.	Jun 2005	A1
20050137693	Haug et al.	Jun 2005	A1
20050137695	Salahieh et al.	Jun 2005	A1
20050137701	Salahieh et al.	Jun 2005	A1
20050154444	Quadri	Jul 2005	A1
20050159811	Lane	Jul 2005	A1
20050182483	Osborne et al.	Aug 2005	A1
20050182486	Gabbay	Aug 2005	A1
20050203616	Cribier	Sep 2005	A1
20050216079	MaCoviak	Sep 2005	A1
20050234546	Nugent et al.	Oct 2005	A1
20050283231	Haug et al.	Dec 2005	A1
20060020247	Kagan et al.	Jan 2006	A1
20060020327	Lashinski et al.	Jan 2006	A1
20060020334	Lashinski et al.	Jan 2006	A1
20060052802	Sterman et al.	Mar 2006	A1
20060052867	Revuelta et al.	Mar 2006	A1
20060058872	Salahieh et al.	Mar 2006	A1
20060064120	Levine et al.	Mar 2006	A1
20060095115	Bladillah et al.	May 2006	A1
20060106454	Osborne et al.	May 2006	A1
20060116625	Renati et al.	Jun 2006	A1
20060129235	Seguin et al.	Jun 2006	A1
20060149360	Schwammenthal et al.	Jul 2006	A1
20060161265	Levine et al.	Jul 2006	A1
20060173537	Yang et al.	Aug 2006	A1
20060195183	Navia et al.	Aug 2006	A1
20060212110	Osborne et al.	Sep 2006	A1
20060224232	Chobotov	Oct 2006	A1
20060241745	Solem	Oct 2006	A1
20060253191	Salahieh et al.	Nov 2006	A1
20060259135	Navia et al.	Nov 2006	A1
20060259136	Nguyen et al.	Nov 2006	A1
20060265056	Nguyen et al.	Nov 2006	A1
20060287717	Rowe et al.	Dec 2006	A1
20060287719	Rowe et al.	Dec 2006	A1
20060293698	Douk	Dec 2006	A1
20060293745	Carpentier et al.	Dec 2006	A1
20070010876	Salahieh et al.	Jan 2007	A1
20070016286	Herrmann et al.	Jan 2007	A1
20070043435	Seguin et al.	Feb 2007	A1
20070050020	Spence	Mar 2007	A1
20070050021	Johnson	Mar 2007	A1
20070067016	Jung	Mar 2007	A1
20070100432	Case et al.	May 2007	A1
20070118206	Colgan et al.	May 2007	A1
20070118207	Amplatz et al.	May 2007	A1
20070129794	Realyvasquez	Jun 2007	A1
20070142906	Figulla et al.	Jun 2007	A1
20070162107	Haug et al.	Jul 2007	A1
20070185559	Shelso	Aug 2007	A1
20070213813	Von Segesser et al.	Sep 2007	A1
20070219620	Eells et al.	Sep 2007	A1
20070233228	Eberhardt et al.	Oct 2007	A1
20070250151	Pereira	Oct 2007	A1
20070255391	Hojeibane et al.	Nov 2007	A1
20070255394	Ryan	Nov 2007	A1
20070265656	Amplatz et al.	Nov 2007	A1
20070270932	Headley et al.	Nov 2007	A1
20070270937	Leanna	Nov 2007	A1
20070293940	Schaeffer et al.	Dec 2007	A1
20080009934	Schneider et al.	Jan 2008	A1
20080021546	Patz et al.	Jan 2008	A1
20080071361	Tuval et al.	Mar 2008	A1
20080071362	Tuval et al.	Mar 2008	A1
20080071363	Tuval et al.	Mar 2008	A1
20080071366	Tuval et al.	Mar 2008	A1
20080071369	Tuval et al.	Mar 2008	A1
20080082164	Friedman	Apr 2008	A1
20080082165	Wilson et al.	Apr 2008	A1
20080082166	Styrc et al.	Apr 2008	A1
20080087581	Eisenhut et al.	Apr 2008	A1
20080097571	Denison et al.	Apr 2008	A1
20080114441	Rust et al.	May 2008	A1
20080125853	Bailey et al.	May 2008	A1
20080125859	Salahieh et al.	May 2008	A1
20080133003	Seguin et al.	Jun 2008	A1
20080140175	Boucher et al.	Jun 2008	A1
20080140189	Nguyen et al.	Jun 2008	A1
20080147179	Cai et al.	Jun 2008	A1
20080147183	Styrc	Jun 2008	A1
20080154358	Tansley et al.	Jun 2008	A1
20080161911	Revuelta et al.	Jul 2008	A1
20080177381	Navia et al.	Jul 2008	A1
20080183273	Mesana et al.	Jul 2008	A1
20080208307	Ben-Muvhar et al.	Aug 2008	A1
20080208328	Antocci et al.	Aug 2008	A1
20080208332	Lamphere et al.	Aug 2008	A1
20080221672	Lamphere et al.	Sep 2008	A1
20080228201	Zarbatany et al.	Sep 2008	A1
20080228254	Ryan	Sep 2008	A1
20080243233	Ben-Muvhar et al.	Oct 2008	A1
20080243245	Thambar et al.	Oct 2008	A1
20080255660	Guyenot et al.	Oct 2008	A1
20080255661	Straubinger et al.	Oct 2008	A1
20080262596	Xiao	Oct 2008	A1
20080262603	Giaquinta et al.	Oct 2008	A1
20080269878	Iobbi	Oct 2008	A1
20080275549	Rowe	Nov 2008	A1
20080288062	Andrieu et al.	Nov 2008	A1
20080319526	Hill et al.	Dec 2008	A1
20090005863	Goetz et al.	Jan 2009	A1
20090012602	Quadri	Jan 2009	A1
20090054976	Tuval et al.	Feb 2009	A1
20090062908	Bonhoeffer et al.	Mar 2009	A1
20090076531	Richardson et al.	Mar 2009	A1
20090076585	Hendriksen et al.	Mar 2009	A1
20090076598	Salahieh et al.	Mar 2009	A1
20090082844	Zacharias et al.	Mar 2009	A1
20090082847	Zacharias et al.	Mar 2009	A1
20090088832	Chew et al.	Apr 2009	A1
20090112309	Jaramillo et al.	Apr 2009	A1
20090118744	Wells et al.	May 2009	A1
20090118824	Samkov	May 2009	A1
20090118826	Khaghani	May 2009	A1
20090125096	Chu et al.	May 2009	A1
20090132035	Roth et al.	May 2009	A1
20090138079	Tuval et al.	May 2009	A1
20090149946	Dixon	Jun 2009	A1
20090157175	Benichou	Jun 2009	A1
20090163934	Raschdorf, Jr. et al.	Jun 2009	A1
20090171438	Chuter et al.	Jul 2009	A1
20090171447	Von Segesser et al.	Jul 2009	A1
20090171456	Kveen et al.	Jul 2009	A1
20090177262	Oberti et al.	Jul 2009	A1
20090182407	Leanna et al.	Jul 2009	A1
20090182413	Burkart et al.	Jul 2009	A1
20090188964	Orlov	Jul 2009	A1
20090192601	Rafiee et al.	Jul 2009	A1
20090216314	Quadri	Aug 2009	A1
20090216317	Cromack et al.	Aug 2009	A1
20090222076	Figulla et al.	Sep 2009	A1
20090227992	Nir et al.	Sep 2009	A1
20090234443	Ottma et al.	Sep 2009	A1
20090248132	Bloom et al.	Oct 2009	A1
20090248133	Bloom et al.	Oct 2009	A1
20090258958	Ford	Oct 2009	A1
20090259306	Rowe	Oct 2009	A1
20090264989	Bonhoeffer et al.	Oct 2009	A1
20090264997	Salahieh et al.	Oct 2009	A1
20090270972	Lane	Oct 2009	A1
20090276040	Rowe et al.	Nov 2009	A1
20090281618	Hill et al.	Nov 2009	A1
20090281619	Le et al.	Nov 2009	A1
20090287296	Manasse	Nov 2009	A1
20090287299	Tabor et al.	Nov 2009	A1
20090292350	Eberhardt et al.	Nov 2009	A1
20090306768	Quadri	Dec 2009	A1
20090318871	Zarbatany et al.	Dec 2009	A1
20100004740	Seguin et al.	Jan 2010	A1
20100036479	Hill et al.	Feb 2010	A1
20100049306	House et al.	Feb 2010	A1
20100082089	Quadri et al.	Apr 2010	A1
20100082094	Quadri et al.	Apr 2010	A1
20100094411	Tuval et al.	Apr 2010	A1
20100100167	Bortlein et al.	Apr 2010	A1
20100114299	Ben Muvhar et al.	May 2010	A1
20100114305	Kang et al.	May 2010	A1
20100121461	Sobrino-Serrano et al.	May 2010	A1
20100131054	Tuval et al.	May 2010	A1
20100161027	Orr	Jun 2010	A1
20100168839	Braido et al.	Jul 2010	A1
20100179633	Solem	Jul 2010	A1
20100179647	Carpenter et al.	Jul 2010	A1
20100191326	Alkhatib	Jul 2010	A1
20100217382	Chau et al.	Aug 2010	A1
20100249894	Oba et al.	Sep 2010	A1
20100249908	Chau et al.	Sep 2010	A1
20100256723	Murray	Oct 2010	A1
20100262157	Silver et al.	Oct 2010	A1
20100268332	Tuval et al.	Oct 2010	A1
20100274345	Rust	Oct 2010	A1
20100280606	Naor	Nov 2010	A1
20100298931	Quadri et al.	Nov 2010	A1
20100305685	Millwee et al.	Dec 2010	A1
20100312333	Navia et al.	Dec 2010	A1
20110004296	Lutter et al.	Jan 2011	A1
20110004299	Essinger et al.	Jan 2011	A1
20110015731	Carpentier et al.	Jan 2011	A1
20110022165	Oba et al.	Jan 2011	A1
20110029067	McGuckin, Jr. et al.	Feb 2011	A1
20110137397	Chau et al.	Jun 2011	A1
20110166644	Keeble et al.	Jul 2011	A1
20110178597	Navia et al.	Jul 2011	A9
20110202128	Duffy	Aug 2011	A1
20110208290	Straubinger et al.	Aug 2011	A1
20110208297	Tuval et al.	Aug 2011	A1
20110208298	Tuval et al.	Aug 2011	A1
20110218619	Benichou et al.	Sep 2011	A1
20110224785	Hacohen	Sep 2011	A1
20110264196	Savage et al.	Oct 2011	A1
20110301704	Alfieri et al.	Dec 2011	A1
20110313515	Quadri et al.	Dec 2011	A1
20110319981	Hill et al.	Dec 2011	A1
20110319989	Lane et al.	Dec 2011	A1
20120012487	Tian et al.	Jan 2012	A1
20120016342	Brecker	Jan 2012	A1
20120016411	Tuval	Jan 2012	A1
20120022605	Jahns et al.	Jan 2012	A1
20120022639	Hacohen et al.	Jan 2012	A1
20120022642	Haug et al.	Jan 2012	A1
20120029627	Salahieh et al.	Feb 2012	A1
20120035703	Lutter et al.	Feb 2012	A1
20120035713	Lutter et al.	Feb 2012	A1
20120041550	Salahieh et al.	Feb 2012	A1
20120041551	Spenser et al.	Feb 2012	A1
20120053681	Alkhatib et al.	Mar 2012	A1
20120059452	Boucher et al.	Mar 2012	A1
20120059454	Millwee et al.	Mar 2012	A1
20120078353	Quadri et al.	Mar 2012	A1
20120078360	Rafiee	Mar 2012	A1
20120101571	Thambar et al.	Apr 2012	A1
20120101572	Kovalsky et al.	Apr 2012	A1
20120123529	Levi et al.	May 2012	A1
20120179051	Pfeiffer et al.	Jul 2012	A1
20120179239	Quadri	Jul 2012	A1
20120179243	Yang et al.	Jul 2012	A1
20120185033	Ryan	Jul 2012	A1
20120215303	Quadri et al.	Aug 2012	A1
20120259405	Weber et al.	Oct 2012	A1
20120259409	Nguyen et al.	Oct 2012	A1
20120271398	Essinger et al.	Oct 2012	A1
20120283820	Tseng et al.	Nov 2012	A1
20120290062	McNamara et al.	Nov 2012	A1
20120296418	Bonyuet et al.	Nov 2012	A1
20120303116	Gorman, III et al.	Nov 2012	A1
20120310328	Olson et al.	Dec 2012	A1
20120323316	Chau et al.	Dec 2012	A1
20120330409	Haug et al.	Dec 2012	A1
20130006294	Kashkarov et al.	Jan 2013	A1
20130018458	Yohanan et al.	Jan 2013	A1
20130030418	Taft et al.	Jan 2013	A1
20130030523	Padala et al.	Jan 2013	A1
20130046378	Millwee et al.	Feb 2013	A1
20130053949	Pintor et al.	Feb 2013	A1
20130053950	Rowe et al.	Feb 2013	A1
20130095264	Sowinski et al.	Apr 2013	A1
20130096671	Iobbi	Apr 2013	A1
20130110226	Gurskis	May 2013	A1
20130110227	Quadri et al.	May 2013	A1
20130110230	Solem	May 2013	A1
20130116777	Pintor et al.	May 2013	A1
20130131788	Quadri et al.	May 2013	A1
20130131793	Quadri et al.	May 2013	A1
20130138203	Quadri	May 2013	A1
20130138207	Quadri et al.	May 2013	A1
20130144375	Giasolli et al.	Jun 2013	A1
20130144378	Quadri et al.	Jun 2013	A1
20130144380	Quadri et al.	Jun 2013	A1
20130144381	Quadri et al.	Jun 2013	A1
20130150956	Yohanan et al.	Jun 2013	A1
20130166024	Drews et al.	Jun 2013	A1
20130172983	Clerc et al.	Jul 2013	A1
20130184813	Quadri et al.	Jul 2013	A1
20130184814	Huynh et al.	Jul 2013	A1
20130236889	Kishimoto et al.	Sep 2013	A1
20130238087	Taylor	Sep 2013	A1
20130245615	Koltz	Sep 2013	A1
20130245736	Alexander et al.	Sep 2013	A1
20130253635	Straubinger et al.	Sep 2013	A1
20130253637	Wang et al.	Sep 2013	A1
20130253639	Alkhatib	Sep 2013	A1
20130253641	Lattouf	Sep 2013	A1
20130253642	Brecker	Sep 2013	A1
20130261737	Costello	Oct 2013	A1
20130261738	Clague et al.	Oct 2013	A1
20130268069	Zakai et al.	Oct 2013	A1
20130289695	Tian et al.	Oct 2013	A1
20130304200	McLean et al.	Nov 2013	A1
20130310928	Morriss et al.	Nov 2013	A1
20130325098	Desai et al.	Dec 2013	A1
20130325121	Whatley et al.	Dec 2013	A1
20130331714	Manstrom et al.	Dec 2013	A1
20130338764	Thornton et al.	Dec 2013	A1
20130338765	Braido et al.	Dec 2013	A1
20130345786	Behan	Dec 2013	A1
20130345803	Bergheim, III	Dec 2013	A1
20140018912	Delaloye et al.	Jan 2014	A1
20140031930	Keidar et al.	Jan 2014	A1
20140039611	Lane et al.	Feb 2014	A1
20140039612	Dolan	Feb 2014	A1
20140039614	Delaloye et al.	Feb 2014	A1
20140044689	Liu et al.	Feb 2014	A1
20140046219	Sauter et al.	Feb 2014	A1
20140046427	Michalak	Feb 2014	A1
20140052237	Lane et al.	Feb 2014	A1
20140052242	Revuelta et al.	Feb 2014	A1
20140081393	Hasenkam et al.	Mar 2014	A1
20140086934	Shams	Mar 2014	A1
20140088685	Yevzlin et al.	Mar 2014	A1
20140088694	Rowe et al.	Mar 2014	A1
20140100420	Mortier et al.	Apr 2014	A1
20140100651	Kheradvar et al.	Apr 2014	A1
20140100653	Savage et al.	Apr 2014	A1
20140107761	Gale et al.	Apr 2014	A1
20140142694	Tabor et al.	May 2014	A1
20140163668	Rafiee	Jun 2014	A1
20140186417	Trollsas et al.	Jul 2014	A1
20140194978	Seguin et al.	Jul 2014	A1
20140194981	Menk et al.	Jul 2014	A1
20140194982	Kovalsky et al.	Jul 2014	A1
20140194983	Kovalsky et al.	Jul 2014	A1
20140214153	Ottma et al.	Jul 2014	A1
20140214154	Nguyen et al.	Jul 2014	A1
20140214155	Kelley	Jul 2014	A1
20140214160	Naor	Jul 2014	A1
20140215791	Soundararajan et al.	Aug 2014	A1
20140221823	Keogh et al.	Aug 2014	A1
20140222136	Geist et al.	Aug 2014	A1
20140222139	Nguyen et al.	Aug 2014	A1
20140222142	Kovalsky et al.	Aug 2014	A1
20140230515	Tuval et al.	Aug 2014	A1
20140236288	Lambrecht et al.	Aug 2014	A1
20140243966	Garde et al.	Aug 2014	A1
20140249622	Carmi et al.	Sep 2014	A1
20140256035	Strasly et al.	Sep 2014	A1
20140257467	Lane et al.	Sep 2014	A1
20140257475	Gross et al.	Sep 2014	A1
20140257476	Montorfano et al.	Sep 2014	A1
20140277390	Ratz et al.	Sep 2014	A1
20140277402	Essinger et al.	Sep 2014	A1
20140277422	Ratz et al.	Sep 2014	A1
20140277423	Alkhatib et al.	Sep 2014	A1
20140277427	Ratz et al.	Sep 2014	A1
20140296973	Bergheim et al.	Oct 2014	A1
20140296975	Tegels et al.	Oct 2014	A1
20140303719	Cox et al.	Oct 2014	A1
20140309728	Dehdashtian et al.	Oct 2014	A1
20140309731	Quadri et al.	Oct 2014	A1
20140309732	Solem	Oct 2014	A1
20140324160	Benichou et al.	Oct 2014	A1
20140324164	Gross et al.	Oct 2014	A1
20140336754	Gurskis et al.	Nov 2014	A1
20140350565	Yacoby et al.	Nov 2014	A1
20140350666	Righini	Nov 2014	A1
20140356519	Hossainy et al.	Dec 2014	A1
20140358223	Rafiee et al.	Dec 2014	A1
20140364404	Cleek et al.	Dec 2014	A1
20140364944	Lutter et al.	Dec 2014	A1
20140370071	Chen et al.	Dec 2014	A1
20140371845	Tuval et al.	Dec 2014	A1
20140371847	Madrid et al.	Dec 2014	A1
20140371848	Murray, III et al.	Dec 2014	A1
20140379067	Nguyen et al.	Dec 2014	A1
20140379068	Thielen et al.	Dec 2014	A1
20140379077	Tuval et al.	Dec 2014	A1
20150012085	Salahieh et al.	Jan 2015	A1
20150018938	Von Segesser et al.	Jan 2015	A1
20150018944	O'Connell et al.	Jan 2015	A1
20150032153	Quadri et al.	Jan 2015	A1
20150045881	Lim	Feb 2015	A1
20150066140	Quadri et al.	Mar 2015	A1
20150081009	Quadri et al.	Mar 2015	A1
20150086603	Hossainy et al.	Mar 2015	A1
20150088252	Jenson et al.	Mar 2015	A1
20150105856	Rowe et al.	Apr 2015	A1
20150142103	Vidlund	May 2015	A1
20150148731	McNamara et al.	May 2015	A1
20150157458	Thambar et al.	Jun 2015	A1
20150209137	Quadri et al.	Jul 2015	A1
20150209141	Braido et al.	Jul 2015	A1
20150216653	Freudenthal	Aug 2015	A1
20150216655	Lane et al.	Aug 2015	A1
20150238315	Rabito et al.	Aug 2015	A1
20150257878	Lane et al.	Sep 2015	A1
20150305864	Quadri et al.	Oct 2015	A1
20150328000	Ratz et al.	Nov 2015	A1
20150342736	Rabito et al.	Dec 2015	A1
20160038281	Delaloye et al.	Feb 2016	A1

Foreign Referenced Citations (74)

Number	Date	Country
2304325	Oct 2000	CA
101262833	Sep 2008	CN
3128704	Feb 1983	DE
102006052564	Dec 2007	DE
0657147	Jun 1995	EP
1255510	Apr 2007	EP
1472996	Sep 2009	EP
2566416	Mar 2013	EP
1264471	Jun 1961	FR
1315844	May 1973	GB
2245495	Jan 1992	GB
2398245	Aug 2004	GB
2002540889	Dec 2002	JP
2008541865	Nov 2008	JP
9749355	Dec 1997	WO
0053104	Sep 2000	WO
0061034	Oct 2000	WO
0135861	May 2001	WO
0135870	May 2001	WO
0172239	Oct 2001	WO
0236048	May 2002	WO
0238084	May 2002	WO
03028522	Apr 2003	WO
03092554	Nov 2003	WO
2004014257	Feb 2004	WO
2004014474	Feb 2004	WO
2004058097	Jul 2004	WO
2005011534	Feb 2005	WO
2005041810	May 2005	WO
2005087140	Sep 2005	WO
2006070372	Jul 2006	WO
2006085304	Aug 2006	WO
2006089236	Aug 2006	WO
2006097931	Sep 2006	WO
2006113906	Oct 2006	WO
2006127765	Nov 2006	WO
2007025028	Mar 2007	WO
2007034488	Mar 2007	WO
2007058857	May 2007	WO
2007097983	Aug 2007	WO
2007122459	Nov 2007	WO
2007123658	Nov 2007	WO
2007134290	Nov 2007	WO
2008005535	Jan 2008	WO
2008013915	Jan 2008	WO
2008070797	Jun 2008	WO
2008091515	Jul 2008	WO
2008103722	Aug 2008	WO
2008150529	Dec 2008	WO
2009026563	Feb 2009	WO
2009033469	Mar 2009	WO
2009045331	Apr 2009	WO
2009052188	Apr 2009	WO
2009053497	Apr 2009	WO
2009091509	Jul 2009	WO
2009094500	Jul 2009	WO
2009108615	Sep 2009	WO
2009134701	Nov 2009	WO
2009137359	Nov 2009	WO
2009149462	Dec 2009	WO
2009155561	Dec 2009	WO
2010004546	Jan 2010	WO
2010008549	Jan 2010	WO
2010037141	Apr 2010	WO
2010040009	Apr 2010	WO
2010057262	May 2010	WO
2010098857	Sep 2010	WO
2010138853	Dec 2010	WO
2011025945	Mar 2011	WO
2011072084	Jun 2011	WO
2011109813	Sep 2011	WO
2012035279	Mar 2012	WO
2012162228	Nov 2012	WO
2012177942	Dec 2012	WO

Related Publications (1)

	Number	Date	Country
	20200146818 A1	May 2020	US

Provisional Applications (3)

Number	Date	Country
61414879	Nov 2010	US
61393860	Oct 2010	US
61331799	May 2010	US

Divisions (1)

	Number	Date	Country
Parent	13096572	Apr 2011	US
Child	14046606		US

Continuations (2)

	Number	Date	Country
Parent	15682890	Aug 2017	US
Child	16659354		US
Parent	14046606	Oct 2013	US
Child	15682890		US

Transcatheter mitral valve prosthesis

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

US

CPC

International Classifications

Abstract